epirubicin has been researched along with Bladder Cancer in 308 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (6.49) | 18.7374 |
| 1990's | 111 (36.04) | 18.2507 |
| 2000's | 90 (29.22) | 29.6817 |
| 2010's | 70 (22.73) | 24.3611 |
| 2020's | 17 (5.52) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, J; Huang, Q; Huo, F; Jia, R; Li, PC; Theodorescu, D; Wang, J; Wang, Y; Yan, C; Yang, J; Yu, H; Zhang, Y | 1 |
| Audenet, F; Brunelle, S; Compérat, E; Houédé, N; Lanz, C; Larré, S; Masson-Lecomte, A; Méjean, A; Neuzillet, Y; Pignot, G; Rollin, P; Roumiguié, M; Rouprêt, M; Xylinas, E | 1 |
| Allory, Y; Audenet, F; Leon, P; Loriot, Y; Masson-Lecomte, A; Neuzillet, Y; Pradère, B; Roumiguié, M; Roupret, M; Saint, F; Seisen, T; Traxer, O; Xylinas, E | 1 |
| Niu, X; Wang, T; Zhong, B | 1 |
| Ding, Z; Gan, Z; Gong, H; Jiao, B; Liu, K; Ren, J; Xu, X; Yu, Q; Zhang, G | 1 |
| Bu, H; Ding, L; Guo, Y; Huang, T; Huo, F; Jia, R; Li, P; Li, W; Li, Y; Wang, L; Yan, C; Zhang, W; Zhang, Y | 1 |
| Budaya, TN; Daryanto, B; Purnomo, AF; Seputra, KP | 1 |
| Balatoni, T; Biró, K; Danyi, T; Géczi, L; Küronya, Z; Liszkay, G; Tóth, E | 1 |
| Cai, S; Chen, J; Chen, P; Fang, Z; Tang, Y; Wu, S; Zhou, Y | 1 |
| Brummelhuis, ISG; Crezee, J; Witjes, JA | 1 |
| Ambite, I; Babjuk, M; Cavalera, M; Chaudhuri, A; Esmaeili, P; Hien, TT; Sabari, S; Svanborg, C; Wan, MLY | 1 |
| El-Kappany, H; El-Nahas, AR; El-Shabrawy, M; Harraz, AM; Osman, Y | 1 |
| Diao, WL; Guo, HQ; Wang, TW; Yang, R; Yuan, H; Zhao, XZ | 1 |
| Gu, H; Hou, J; Liu, H; Lu, J; Miao, H; Shen, F; Xue, Y | 1 |
| Dong, B; Fu, X; Han, B; Luo, Y; Men, H; Meng, M; Tian, S; Yuan, L; Zhang, F; Zhang, S | 1 |
| Alsyouf, M; Groegler, J; Hu, B; Pierorazio, P | 1 |
| Chen, J; Chen, L; Huang, B; Huang, G; Li, W; Mao, X | 1 |
| Cao, Y; Chu, C; Liu, Z; Lu, J; Wu, C; Zhang, Y | 1 |
| Cao, CF; Gao, J; Liang, HZ; Wang, WM; Zhao, H | 1 |
| Chen, L; Cui, XG; Gao, Y; Huang, H; Pan, XW; Wang, LH; Xu, DF; Yang, QW | 1 |
| Chung, JI; Hwang, H; Kim, TS; Noh, GH | 1 |
| Gou, X; Gu, W; Liu, Y; Yin, H | 1 |
| Cozar-Olmo, JM; Fernandez-Gomez, JM; Juárez, A; Martínez-Piñeiro, L; Palou, J; Unda-Urzaiz, M | 1 |
| Fang, Z; Hao, Y; Hu, X; Li, J; Li, L; Liu, X; Tan, M; Wang, Q; Wu, C; Wu, Q; Wu, Y; Xu, J; Yang, X; Yang, Z; Zhao, J | 1 |
| Chen, J; Chen, L; Fan, W; Huang, B; Qiu, S; Yao, Z; Zheng, J | 1 |
| Ali-El-Dein, B; Bazeed, MA; El-Assmy, AM; Elsawy, AA | 1 |
| Chen, J; Chen, L; Fan, W; Huang, B; Lin, H; Qiu, S; Wang, H; Yao, Z; Zheng, J | 1 |
| Chen, X; Ding, J; Shan, H; Wang, C; Wang, G; Wang, J; Wang, X; Zhuang, X | 1 |
| Cui, M; Ding, J; Gao, X; Jiang, S; Jin, X; Jin, Y; Li, N; Sun, X; Suo, N; Wang, M; Zhang, H; Zheng, J | 1 |
| Chen, W; Cui, W; Fan, W; Li, J; Lian, F; Liu, Y; Shen, L; Wang, Y; Zhao, Y | 1 |
| Chan, MW; Chen, LG; Chen, SY; Hsieh, HY; Hsu, CD; Lin, MY; Lu, CC; Shen, CH | 1 |
| Chen, J; Chen, L; Li, J; Qiu, S; Wang, Y; Yang, J; Yao, Z | 1 |
| Fujii, Y; Hosoda, C; Ikeda, M; Kamigaito, T; Komatsu, H; Kurosawa, K; Miyakawa, J; Motoshima, T; Okaneya, T | 1 |
| Alfred Witjes, J; Arentsen, HC; Falke, J; Høgset, A; Oosterwijk, E | 1 |
| Hellström, P; Hemdan, T; Jahnson, S; Johansson, R; Malmström, PU; Tasdemir, I | 1 |
| Arends, TJ; van der Heijden, AG; Witjes, JA | 1 |
| Chi, Y; Song, Y; Wang, J; Yang, L; Zhou, A | 1 |
| Kawamura, N; Matsushita, M; Nin, M; Okada, T; Tsujihata, M; Ujike, T | 1 |
| Brausi, MA; de Reijke, TM; Kirkels, WJ; Oddens, JR; Oosterlinck, W; Prescott, S; Sylvester, RJ; van Andel, G; van de Beek, C; Witjes, JA | 1 |
| Kamat, AM; Lamm, DL | 1 |
| Chen, M; Han, XM; Li, T; Li, WC; Liu, SC; Xing, Y | 1 |
| Endo, H; Inoue, M; Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, H; Yoshida, T | 1 |
| Ahmed, SM; Jin, X; Kakehi, Y; Kanematsu, A; Li, Y; Nojima, M; Sugimoto, M; Suzuki, T; Togo, Y; Wu, X; Yamamoto, S; Zhang, X | 1 |
| Cheng, Y; Deng, X; Li, X; Liu, X; Lu, Q; Qin, C; Yang, X; Yin, C; Zhang, X; Zhao, R | 1 |
| Decaestecker, K; Lumen, N; Oosterlinck, W; Ringoir, A | 1 |
| Bianco, V; Fiaschi, AI; Francini, E; Laera, L; Miano, ST; Petrioli, R; Roviello, G | 1 |
| Burnett, B; Chatta, D; Cottrell, L; Laverty, G; McConville, C | 1 |
| Ali-El-Dein, B; Babjuk, M; Birtle, A; De Nunzio, C; Gudjonsson, S; Holmang, S; Inman, BA; Kaasinen, E; N'Dow, J; Oddens, JR; Okamura, K; Oosterlinck, W; Solsona, E; Sydes, MR; Sylvester, RJ; Tatar, CA | 1 |
| Kato, T; Komiya, A; Kondo, F; Nomura, K; Wakisaka, M | 1 |
| Hashimoto, Y; Hatakeyama, S; Hosogoe, S; Imai, A; Koie, T; Mori, K; Ohyama, C; Tobisawa, Y; Yamamoto, H; Yoneyama, T | 1 |
| Baretton, GB; Froehner, M; Hakenberg, OW; Heberling, U; Hübler, M; Koch, R; Novotny, V; Oehlschlaeger, S; Wirth, MP | 1 |
| Cheng, Y; Deng, X; Li, X; Liu, X; Lu, Q; Qin, C; Yang, X; Yin, C; Zhao, R | 1 |
| Cao, JW; Chen, L; Cui, XG; Gao, Y; Hong, Y; Huang, H; Huang, Y; Li, L; Pan, XW; Ren, JZ; Xu, DF | 1 |
| Chang, HY; Chang, TC; Chen, SH; Chow, NH; Huang, WY; Lee, CT; Tsai, YS; Tzai, TS; Yen, CJ | 1 |
| Aaltomaa, S; Boström, P; Hellström, P; Järvinen, R; Kaasinen, E; Leskinen, M; Liukkonen, T; Marttila, T; Raitanen, M; Rintala, E; Seppänen, M; Tammela, T | 1 |
| Chang, LC; Kuo, YL; Lin, KJ; Liu, CW; Wu, YT; Yu, TJ | 1 |
| Jeong, CW; Kang, M; Kim, HH; Ku, JH; Kwak, C | 1 |
| Chen, B; Chen, Q; Huang, J; Lv, X; Qin, X; Zhan, X; Zhuo, Y | 1 |
| Cui, H; Jiang, R; Li, X; Lin, X; Liu, C; Tao, R; Tian, S; Zhuang, H; Zhuo, C | 1 |
| Colombel, MC | 1 |
| Boorjian, SA; Lu, DD; Raman, JD | 1 |
| Chen, JF; Cheng, Y; Lv, XY; Ma, L; Ma, Q; Yu, BX; Yu, R | 1 |
| Chang, X; Miao, C; Ni, H; Tang, Q; Wu, C; Zhang, J; Zhou, X | 1 |
| Engeler, DS; Hobi, C; Müller, J; Neyer, M; Schmid, HP; Wyler, S | 1 |
| Oosterlinck, W; Sylvester, R | 1 |
| O'Donnell, M; Oosterlinck, W; Sylvester, RJ | 1 |
| Azuma, H; Katsuoka, Y; Nishida, T; Nomi, H; Segawa, N; Takahara, K | 1 |
| Adell, L; Bendahl, PO; Davidsson, T; Grabe, M; Gudjónsson, S; Hagberg, G; Larsson, B; Liedberg, F; Månsson, W; Merdasa, F; Olsson, R; Richthoff, J | 1 |
| Herr, HW | 1 |
| Goya, N; Hashimoto, Y; Iida, S; Kobayashi, H; Kondo, T; Tanabe, K | 1 |
| Constantinides, CA; Mihalakis, A; Stravodimos, KG; Tyritzis, SI | 1 |
| Chua, CW; Han, HY; Hu, H; Ling, MT; Wang, XF; Wang, YL; Wong, YC; Xu, KX; Zhang, XP | 1 |
| Boström, PJ; Laato, M; Laihia, JK; Leino, L; Pylkkänen, L | 1 |
| Birch, BR; Cooper, AJ; Featherstone, JM; Hayes, MC; Lwaleed, BA; Speers, AG | 2 |
| Fuse, H; Imamura, T; Kaji, K; Oishi, N; Okumura, A | 1 |
| Birare, N; Cooper, AJ; Lwaleed, BA | 1 |
| Duchek, M; Hellsten, S; Hellström, P; Jahnson, S; Johansson, R; Malmström, PU; Mestad, O | 1 |
| Babjuk, M | 1 |
| Brausi, MA; Calais Da Silva, F; de Reijke, TM; Gorlia, T; Hoeltl, W; Kirkali, Z; Kirkels, WJ; Powell, PH; Prescott, S; Sylvester, RJ; van de Beek, C | 1 |
| Kumon, H; Miyaji, Y; Nasu, Y; Saegusa, M; Saika, T; Takeda, K; Tsushima, T | 1 |
| Allegro, R; Altieri, V; Battaglia, M; Di Lallo, A; Falsaperla, M; Melloni, D; Morgia, G; Ruggiero, G; Salzano, L; Sblendorio, D; Serretta, V; Zito, A | 1 |
| Chen, MK; Han, H; Hou, GL; Li, YH; Liu, ZW; Lu, KS; Qin, ZK; Tu, H; Yang, ZW; Yao, K; Ye, YL; Zhang, XQ; Zhang, ZL; Zhou, FJ | 1 |
| Kynaston, H; Mason, MD; Shelley, MD | 1 |
| Hanai, K; Hongoh, S; Inatsuchi, H; Kawakami, M; Nomoto, T; Terachi, T | 1 |
| Cai, T; Luciani, LG; Malossini, G | 1 |
| Çal, Ç; Özen, H; Şahin, H; Tanıdır, Y; Türkeri, L | 1 |
| Bertz, S; Danenberg, KD; Danenberg, PV; Hartmann, A; Hoffmann, AC; Lehmann, J; Leicht, C; Schuler, M; Stöckle, M; Stöhr, R; Wild, P | 1 |
| Drewa, T; Gurtowska, N; Kloskowski, T | 1 |
| Akaza, H; Hinotsu, S; Koga, H; Kume, H; Nagamori, S; Naito, S; Nasu, Y; Noguchi, S; Ozono, S; Samma, S; Sumiyoshi, Y; Tanaka, Y; Terai, A; Tomita, Y; Tsushima, T; Uemura, H; Yamaguchi, A | 1 |
| Han, B; Liu, H; Ruan, Y; Sun, X; Xia, S; Xue, S | 1 |
| Jiang, L; Kwong, J; Shang, PF; Tian, J; Tian, JQ; Wang, ZP; Yang, K; Yue, ZJ | 1 |
| Caris, CT; Hendricksen, K; Janzing-Pastors, MH; Lammers, RJ; Witjes, JA; Witjes, WP | 1 |
| Cao, M; Chen, HG; Ma, CK; Ma, J; Xue, W | 1 |
| Matsuo, T; Miyata, Y; Ohba, K; Sagara, Y; Sakai, H; Takahashi, H; Watanabe, S | 1 |
| Chu, Y; Jin, X; Kakehi, Y; Li, J; Li, X; Li, Y; Sun, X; Wang, X; Wu, X; Xu, C; Yu, J | 1 |
| Chuang, CK; Hsu, PH; Hua, MY; Liu, HL; Pang, ST; Tang, HJ; Tsai, RY; Yang, HW; Yen, TC | 1 |
| Ping, SY; Wu, CL; Yu, CP; Yu, DS | 1 |
| Feng, L; Ma, LL; Qu, CX; Tian, Y; Wang, Y; Zhang, YH | 1 |
| Cao, JZ; Chen, W; Lu, J; Luo, JH; Pang, J; Tong, ZT; Wu, RH; Xie, D | 1 |
| Abotouk, N; Halim, A | 1 |
| Allegro, R; Altieri, V; Carrieri, G; Di Lallo, A; Morgia, G; Serretta, V | 1 |
| Nishiyama, T; Takahasi, K; Tanikawa, T; Tomita, Y | 1 |
| Kaasinen, E; Liukkonen, T; Raitanen, M; Rajala, P; Rintala, E | 1 |
| Antonuzzo, A; Chioni, A; Conte, P; Francesca, F; Galli, L; Iannopollo, M; Orlandini, C; Ricci, S; Selli, C; Vocaturo, V | 1 |
| Hayashi, M; Kanetake, H; Kusaba, Y; Noguchi, M; Nomata, K; Sakuragi, T; Shindo, K; Tsuda, N; Yamashita, S | 1 |
| Birch, B; Cooper, A; Lewin, J | 1 |
| Brundage, M; Chin, JL; Lukka, H; Markman, BR; Segal, R; Winquist, E | 1 |
| Anderson, WR; Cooper, AJ; Crook, TJ; Duffy, PM; Harris, NM; Hayes, MC; Sharpe, P; Solomon, LZ | 1 |
| Anderson, WR; Birch, BR; Cooper, AJ; Harris, NM; Lwaleed, BA; Solomon, LZ | 1 |
| Ali-El-Dein, B; Ghoneim, MA; Hinev, A; Ibrahiem, el-HI; Nabeeh, A; Sarhan, O | 1 |
| Koga, H; Kuroiwa, K; Naito, S; Osada, Y; Tsuneyoshi, M; Yamaguchi, A | 1 |
| Amadori, D; Fabbri, F; Frassineti, GL; Gasperi Campani, A; Gunelli, R; Ricotti, L; Tesei, A; Ulivi, P; Zoli, W | 1 |
| Habuchi, T; Kamoto, T; Nakashima, M; Nishiyama, H; Ogawa, O; Yagihashi, Y; Yamamoto, S | 1 |
| Canda, AE; Kirkali, Z; Mungan, MU; Tuzel, E; Yorukoglu, K | 1 |
| Akaza, H; Hinotsu, S; Kotake, T; Kuroda, M; Niijima, T | 1 |
| Ishimura, H; Kajihara, S; Koie, T; Kudoh, S; Suzuki, T; Yoneyama, T | 1 |
| Chan, CK; Chan, LW; Chan, SF; Chan, SY; Cheng, CW; Cheung, HY; Lai, FM; Li, ML; Ng, CF; Wong, WS | 1 |
| Brössner, C; Comploj, E; Lodde, M; Mian, C; Negri, G; Palermo, S; Pycha, A; Staffler, A; Vittadello, F | 1 |
| Akao, T; Habuchi, T; Kato, T; Li, Z; Mitsumori, K; Ohyama, C; Sato, K; Tsuchiya, N | 1 |
| Oddens, JR; Sylvester, R; van der Meijden, AP | 1 |
| Brausi, M; Carpentier, P; de Reijke, TM; Hall, RR; Kurth, KH; Landsoght, KE; Sylvester, RJ; van de Beek, K | 1 |
| Jansen, CF; Schalken, JA; van der Heijden, AG; Verhaegh, G; Witjes, JA | 1 |
| Fujimoto, K; Fukushima, M; Hirao, Y; Matsui, Y; Nishiyama, H; Ogawa, O; Ohshima, S; Ono, Y; Teramukai, S; Watanabe, J | 1 |
| Galsky, MD; Scher, HI | 1 |
| Albers, P; Beck, J; Becker, T; Frohneberg, D; Funke, PJ; Kälble, T; Langbein, S; Lehmann, J; Miller, K; Reiher, F; Retz, M; Roth, S; Schiller, M; Sternberg, D; Stöckle, M; Thüroff, J; Walz, P; Weining, C; Wellek, S; Wiemers, C | 1 |
| Esfahani, F; Mehraban, D | 1 |
| Alamanis, C; Bougas, D; Dimitrakopoulos, A; Giannopoulos, A; Kopterides, P; Kopteridis, P; Kosmas, C; Mitropoulos, D; Skopelitis, H; Stravodimos, K; Tsavaris, N | 1 |
| Chen, BJ; Lin, GB; Rong, RM; Wu, ZB; Wu, ZM | 1 |
| Hale, K; Lamm, DL; McGee, WR | 1 |
| Franzaring, L; Lehmann, J; Stöckle, M; Thüroff, J; Wellek, S | 1 |
| Imazu, T; Ito, S; Sugao, H; Yokomizo, S | 1 |
| Oosterlinck, W | 1 |
| Bonacina, P; Butti, A; Cappoli, S; Esposito, N; Invernizzi, S; Librizzi, A; Locatelli, G; Trinchieri, A | 1 |
| Chen, B; Ding, Q; Liu, B; Wang, Z; Yu, J; Zhang, P; Zhang, Y | 1 |
| Cooper, AJ; Featherstone, JM; Lwaleed, BA; Sallis, BJ; Speers, AG | 1 |
| Adorini, L; Daniel, KC; Penna, G | 1 |
| Cooper, AJ; Harris, NM; Lwaleed, BA; Mackie, SJ; Sharma, DM | 1 |
| Friedrich, MG | 1 |
| Chen, L; Gan, L; Lai, YQ; Li, M; Liu, G; Na, YQ; Yin, ZF; Yuan, YM | 1 |
| Burgués, JP; Gómez, L; Jiménez-Cruz, JF; Ozonas, M; Pontones, JL; Vera, CD | 1 |
| Chuma, M; Harabayashi, T; Higashiyama, H; Hige, S; Nonomura, K; Shinohara, N | 1 |
| Choi, HY; Kang, WK; Kim, WS; Lee, HM; Lim, HY; Park, BB; Park, K; Uhm, JE | 1 |
| Bartoletti, R; Cai, T; Farina, U; Mazzoli, S; Melone, F; Mondaini, N | 1 |
| Fujikawa, N; Hattori, Y; Kakizoe, M; Kishida, T; Kondo, K; Kubota, Y; Nakaigawa, N; Noguchi, K; Saito, K; Takizawa, A; Teranishi, J | 1 |
| McDonald, CE | 1 |
| Cooper, AJ; Featherstone, JM; Lwaleed, BA; Speers, AG | 1 |
| Chow, NH; Tsai, YS; Tzai, TS | 1 |
| Berrum-Svennung, I; Boman, H; Granfors, T; Holmäng, S; Jahnson, S | 1 |
| Fujimoto, N; Hasui, Y; Iguchi, A; Kinukawa, N; Koga, H; Kuramoto, H; Naito, S; Yamaguchi, A | 1 |
| Aglianò, AM; Gazzaniga, P; Gradilone, A; Silvestri, I | 1 |
| Caris, CT; de Bruin, MJ; Hendricksen, K; Idema, JG; Janzing-Pastors, MH; Kums, JJ; van Vierssen Trip, OB; Vergunst, H; Witjes, JA; Witjes, WP | 1 |
| Beltrami, P; Cazzoletti, L; Ruggera, L; Schiavone, D; Zattoni, F | 1 |
| Bartoletti, R; Boddi, V; Cai, T; Mazzoli, S; Mondaini, N; Nesi, G; Tinacci, G; Zini, E | 1 |
| Akagi, T; Matsumura, Y; Nasu, Y; Obama, T; Ohmori, H; Ozaki, Y; Tsushima, T; Yoshimoto, J | 2 |
| Igawa, M; Kadena, H; Ueda, M; Usui, T | 2 |
| Kinouchi, T; Kotake, T; Kuroda, M; Maeda, O; Meguro, N; Saiki, S; Usami, M | 1 |
| Hashine, K; Kasahara, K; Sumiyoshi, Y | 1 |
| Arai, Y; Kanba, T; Shichiri, Y; Yoshida, S | 1 |
| Gertenbach, U; Hohenfellner, R; Huber, C; Meyenburg, W; Stöckle, M; Thüroff, JW; Voges, G; Wellek, S | 2 |
| Coptcoat, M; Masters, JR; Popert, RJ; Zupi, G | 1 |
| Hosaka, M; Kubota, Y; Masuda, M; Noguchi, S; Oouchi, H; Shuin, T | 1 |
| Cocconi, G; Frattini, A; Larosa, M; Leonardi, F; Macaluso, G; Monica, B; Passalacqua, R | 1 |
| Chuchkova, M; Damianov, C; Koleva, P; Terziev, T | 1 |
| Coptcoat, MJ; Goodall, J; Masters, JR; Parmar, MK; Popert, RJ; Thompson, PM | 1 |
| Carbone, A; Dal Bo, V; Francini, M; Lo Re, G; Monfardini, S; Santarossa, S; Talamini, R; Trovò, MG; Veronesi, A | 1 |
| Gertenbach, U; Hohenfellner, R; Huber, C; Meyenburg, W; Rossmann, M; Stöckle, M; Thüroff, JW; Voges, GE; Wellek, S | 1 |
| Kobayashi, H; Obata, K | 1 |
| Hasegawa, Y; Miyake, K; Murase, T; Obata, K; Ohshima, S; Okamura, K; Ono, Y; Sakata, T; Shimoji, T | 1 |
| Koyanagi, T; Maru, A; Nagamori, S; Nonomura, K; Seki, T; Shinohara, N; Takakura, F; Tanaka, M; Togashi, M | 1 |
| Fukushima, S; Hiramatsu, T; Hirao, Y; Momose, H; Ohashi, Y; Okajima, E; Ozono, S; Yoshida, K | 1 |
| Arakawa, S; Eto, H; Hamami, G; Kamidono, S; Nakamura, I; Obe, S; Ogawa, T; Oka, Y; Ueno, K; Yoshimura, K | 1 |
| Abe, B; Hanamoto, N; Higasibori, Y; Inoue, A; Ishida, G; Miyagawa, I; Nakahara, T; Sumi, F; Watanabe, N | 1 |
| Goya, N; Kihara, T; Nakazawa, H; Okumura, T; Onizuka, S; Ryoji, O; Sonoda, T; Tanabe, K; Toma, H; Tomoe, H | 1 |
| Fukushima, S; Furuhata, A; Hosaka, M; Ishizuka, E; Kondo, I; Kubota, Y; Miura, T; Moriyama, M; Noguchi, S; Shuin, T | 1 |
| Hirano, A; Ohkawa, T; Shinka, T; Uekado, Y | 1 |
| Basar, M; Cetin, S; Erol, A; Ozgür, S | 1 |
| Cevoli, R; Cocimano, V; Marino, G; Marten Perolino, R | 1 |
| Corselli, G; Gervasi, F; Lio, D; Pavone-Macaluso, M; Piazza, B; Salerno, S; Serretta, V | 1 |
| Hammond, B; Kurth, KH; Oosterlinck, W; Schröder, F; Sylvester, R | 1 |
| Chionis, HS; Dauaher, HH; Melekos, MD; Paranychianakis, GS | 1 |
| Corselli, G; Ingargiola, GB; Pavone, C; Pavone-Macaluso, M; Serretta, V; Tripi, M | 1 |
| Jones, WG; Newling, DW; Ostrowski, MJ; Sokal, MP | 1 |
| Bultinck, J; Hammond, B; Kurth, KH; Oosterlinck, W; Schröder, F; Sylvester, R | 1 |
| Bader, H; Eisenberger, F; Guhl, L; Jipp, P; Nunnensiek, C; Rassweiler, J; Ruether, U; Schmidt, A; Stilz, S | 1 |
| Alcaraz, A; Alvarez, R; Biete, A; Daniels, M; Mallafré, J; Mendoza Solórzano, L; Segarra, A; Solá, C; Solé, M; Viñolas, N | 1 |
| Lukkarinen, O; Raitanen, MP | 1 |
| Coptcoat, M; Davies, SL; Hickson, ID; Masters, JR; Popert, R | 1 |
| Hasegawa, S; Koga, H; Kotoh, S; Kumazawa, J; Kuwano, M; Naito, S; Yokomizo, A | 1 |
| Akçay, T; Erözenci, A; Konukoğlu, D | 1 |
| Barbanti, G; De Capua, B; De Lauretis, A; Francini, G; Frediani, B; Manganelli, A; Mondillo, S; Petrioli, R; Salvestrini, F | 1 |
| Pavone, C; Pavone-Macaluso, M; Piazza, B; Piazza, S; Serretta, V | 1 |
| Malvestiti, GM; Pozzi, E; Roggia, A | 1 |
| Bondovalli, C; Dall'Oglio, B; Luciano, M; Parma, A; Pegoraro, C; Schiavon, L | 1 |
| Kawaguchi, T; Nishimura, S; Takahashi, N | 1 |
| Cooper, A; Duffy, PM; Hayes, MC; Smart, CJ | 1 |
| Cooper, A; Duffy, PM; Gatrell, SK; Hayes, MC; Smart, CJ | 1 |
| Comella, P; De Lena, M; Durini, E; Fiorillo, C; Lorusso, V; Pagliarulo, A; Riccardi, F; Selvaggi, FP | 1 |
| Bono, AV; Denis, L; Hall, RR; Lovisolo, JA; Sylvester, R | 1 |
| Altug, U; Erol, D; Uygur, MC; Yaman, I | 1 |
| Igawa, M; Ishibe, T; Kadena, H; Kawanishi, M; Shiina, H; Shirakawa, H; Urakami, S; Usui, T | 1 |
| Beysel, M; Erdoğan, K; Erol, A; Sengör, F; Tuzluoğlu, D | 1 |
| Cooper, AJ; Davies, CL; Duffy, PM; Loizidou, MC; MacRobert, AJ; Taylor, I | 1 |
| Willis, RG | 1 |
| Fujita, Y; Inoue, K; Inoue, Y; Kasahara, K; Morioka, M; Shuin, T; Yamashita, M | 1 |
| Flannigan, GM; Hamilton Stewart, PA; Lowe, J; Nargund, VH | 1 |
| Barbalias, G; Chionis, H; Dandinis, K; Dauaher, H; Fokaefs, E; Melekos, MD; Zarakovitis, I | 1 |
| Ali-el-Dein, B; Ashamallah, A; el-Baz, M; Nabeeh, A; Shamaa, S | 1 |
| Ali-el-Dein, B; Aly, AN; Ashamallah, A; el-Baz, M; Shamaa, S | 1 |
| Aravantinos, G; Christodoulou, C; Dimopoulos, K; Fountzilas, G; Giannakakis, T; Kastriotis, I; Kostakopoulos, CA; Linardou, E; Picramenos, D; Skarlos, DV | 1 |
| Aikawa, K; Ishibashi, K; Koseki, K; Ogihara, M; Shiraiwa, Y; Yamaguchi, O | 1 |
| Doi, T; Ehara, H; Fujihiro, S; Fujimoto, Y; Hasegawa, Y; Hayashi, H; Horie, M; Isogai, K; Itoh, F; Kanematsu, M; Kawada, Y; Kobayashi, S; Kuriyama, M; Maeda, S; Matsuda, S; Sakai, S; Takahashi, Y; Takeda, A; Takeuchi, T; Tei, KH; Yamada, S | 1 |
| Bianchi, S; Ferroni, C; Galante, E; Maymone, S; Megale, C; Molinaro, S | 1 |
| Rosen, M | 1 |
| Fukatsu, T; Itoh, H; Kinukawa, T; Kobayashi, H; Kobayashi, M; Matsuura, O; Ohshima, S; Okamura, K; Otani, T; Tsumura, Y | 1 |
| Kumon, H; Miyaji, Y; Nasu, Y; Noda, M; Ohmori, H; Tsushima, T | 1 |
| Akaza, H; Hirao, Y; Hosaka, M; Ito, H; Kotake, T; Koyanagi, T; Kuroda, M; Miyanaga, N; Okajima, E; Saito, Y; Shimazaki, J | 1 |
| Birch, BR; Cooper, AJ; Foley, SJ; Jennings, AM; Solomon, LZ | 1 |
| Kobayashi, M; Kobayashi, Y; Morita, T; Sugaya, Y; Tokue, A; Yuzawa, M | 1 |
| Helle, M; Kaasinen, E; Liukkonen, T; Lukkarinen, O; Raitanen, M; Rajala, P; Rintala, E | 1 |
| Birch, BR; Cooper, AJ; Hayes, MC; Jennings, AM; Sharpe, P; Solomon, LZ | 1 |
| Coptcoat, MJ; Gibson, D; Masters, JR; Parmar, MK; Popert, RJ; Thompson, PM | 1 |
| Bellringer, J; Doherty, AP; Rogers, H; Stirling, R; Trendell-Smith, N | 1 |
| Aota, Y; Yoshida, K | 1 |
| Göğüş, O; Ozdiler, E; Sözen, S; Yaman, O | 1 |
| Goto, Y; Kihara, T; Kondo, T; Nakazawa, H; Onitsuka, S; Ryoji, O; Satoh, T; Toma, H | 1 |
| Arrufat Boix, JM; Cuñat Albert, E; Francisco Mingol, V; Gallego Gómez, J; Pérez Mestre, M | 1 |
| Dagnello, M; Di Corato, R; Tursi, A; Ventura, MT | 1 |
| Ali-El-Dein, B; Ghoneim, MA; Ismail, EH; Nabeeh, A | 1 |
| Ohashi, Y; Yamaguchi, T | 1 |
| Bonavida, B; Miki, T; Mizutani, Y; Yoshida, O | 1 |
| Akaza, H; Hinotsu, S; Kotake, T; Ohashi, Y | 1 |
| Baltaci, S; Bedük, Y; Soygür, T; Tokgöz, G; Yaman, O | 1 |
| Malmström, P | 1 |
| Goa, KL; Onrust, SV; Wiseman, LR | 1 |
| Griffiths, TR; Hall, RR; Lunec, J; Marsh, C; Neal, DE; Qureshi, KN; Roberts, JT; Robinson, MC | 1 |
| Lohrisch, C; Murray, N; Pickles, T; Sullivan, L | 1 |
| Melekos, MD; Moutzouris, GD | 1 |
| Duque, JL; Loughlin, KR | 1 |
| Aspropotamitis, A; Athanassiou, A; Dimitriadis, M; Halikia, A; Karvounis, N; Pectasides, D; Visvikis, A | 1 |
| Bono, AV; Lovisolo, JA; Saredi, G | 1 |
| Koshikawa, T; Nakashima, N; Ohshima, S; Schenck, U; Takashi, M | 1 |
| Aki, FT; Aygün, C; Bilen, CY; Ekici, S; Kendi, S; Ozen, H | 1 |
| Baselli, EC; Greenberg, RE | 1 |
| Aoki, Y; Arai, Y; Maeda, H; Maekawa, S; Ogura, K; Ohkubo, K; Okada, T; Suzuki, H | 1 |
| Fischer, C; Lehmann, J; Loch, T; Pinkenburg, FA; Retz, M; Seppelt, U; Stöckle, M; Timm, KJ; Trocha, C; Wellek, S | 1 |
| Cervenakov, I; Chovan, D; Mala, M; Mardiak, J; Slavov, D; Szoldova, K | 1 |
| Baresi, A; Borin, R; Caruso, GM; Catanzaro, F; Comeri, CG; Conti, G; Lissoni, G; Minocci, D; Monesi, G; Perego, S; Pino, R; Risi, O; Scardino, G; Torelli, F | 1 |
| Hosaka, M; Ikeda, I; Kawakami, S; Kubota, Y; Masuda, M; Noguchi, S; Ohuchi, H; Saito, K; Takase, K; Yao, M | 1 |
| Brausi, M; de Balincourt, C; Kirkels, W; Sylvester, R; van der Meijden, AP; Zambon, V | 1 |
| Masters, JR | 1 |
| Hayashi, Y; Ito, Y; Kawai, N; Kohri, K; Okamura, T; Sasaki, S; Tozawa, K | 1 |
| Bono, AV; Brausi, M; de Balincourt, C; Hall, R; Mack, D; Oosterlinck, W; Sylvester, R | 1 |
| Akaza, H; Hinotsu, S; Isaka, S; Kagawa, S; Koiso, K; Kotake, T; Machida, T; Matsumura, Y; Niijima, T; Obata, K; Ohashi, Y; Ohe, H; Shimazaki, J; Tashiro, K | 1 |
| Bakirtaş, H; Ersoy, H; Imamoğlu, MA; Sertçelik, AN; Yiğitbaşi, O | 1 |
| Chen, B; Ding, Q; Jiang, H; Liu, B; Wang, J; Wang, Z; Zhang, Y | 1 |
| Błaszczyk, J; Kaczmarek, P; Kowalski, J; Niemirowicz, J | 1 |
| Baltaci, S; Bedük, Y; Göğüş, O; Müftüoğlu, YZ; Türkölmez, K | 1 |
| Bassi, P; Longo, F; Pagano, F; Pappagallo, GL; Saraeb, S; Spinadin, R; Zattoni, F | 1 |
| Mauceri, G; Mazzone, G; Morgia, G; Motta, M | 1 |
| Furukawa, Y; Hayashi, J; Hidaka, N; Kato, M; Ohashi, N; Sanda, M; Yajima, Y | 1 |
| Kojima, M; Mishina, T; Nakagawa, S; Ohe, H; Watanabe, H | 1 |
| Debruyne, FM; Kurth, KH; Oosterlinck, W; van der Meijden, AP | 1 |
| Beghelli, R; Bercovich, E; Corrado, G; Lelli, G; Mannini, D; Maver, P; Melotti, B; Pannuti, F; Rossi, AP; Severini, G | 1 |
| Bub, P; Eisenberger, F; Rüther, U; Schmidt, A | 1 |
| Arnone, S; Cerullo, G; Dal Pozzo, C; Fornarola, V; Montanari, F; Suprani, G; Voce, S | 1 |
| Hoch, V; Noll, F; Schreiter, F | 1 |
| Akiyama, M; Inoue, Y; Sumiyoshi, Y; Yokota, K | 1 |
| Koyama, I; Nishino, S; Toma, H; Tomoe, H; Uda, M | 1 |
| Brandão, T; da Silva, FC; Ferrito, F; Santos, A | 1 |
| Corselli, G; Pavone, C; Pavone-Macaluso, M; Serretta, V | 1 |
| Castagnetti, G; Ferrari, G; Ferrari, P; Grassi, D; Pollastri, CA; Tavoni, F | 1 |
| Crawford, ED; Thrasher, JB | 1 |
| Barbalias, G; Dauaher, H; Fokaefs, E; Melekos, MD | 1 |
| Barbieri, F; Berri, G; Brausi, M; Castagnetti, G; Federico, M; Frassoldati, A; Palladini, PP; Pollastri, C; Silingardi, V | 1 |
| Akiyama, M; Sumiyoshi, Y; Yokota, K | 1 |
| Newling, DW | 1 |
| Corselli, G; Pavone, C; Pavone-Macaluso, M; Pizzuto Antinoro, SA; Serretta, V | 1 |
| Bogdanowicz, JF; Carpentier, PJ; Kurth, K; ten Kate, F; Van Reyswoud, I; Vijgh, WJ | 1 |
| Hall, RR; Macneil, HF; Neal, DE; Roberts, JT | 1 |
| Hellström, P; Kontturi, M; Lukkarinen, O; Nurmi, M; Ottelin, J; Paul, C; Puntala, P; Tammela, T; Tidefeldt, U | 1 |
| Ali, NM; Eissa, S; Elattar, I; Elsebai, I; Gad el Mawla, N; Habboubi, N; Hamza, MR; Khaled, H; Magrath, I; Mansour, MA | 1 |
| Cumming, JA; Garvie, WH; Hargreave, TB; Kirk, D; Newling, DW; Robinson, MR; Smith, PH; Whelan, P | 1 |
| Chisholm, GD; Hargreave, TB; James, K; Prescott, S; Smyth, JF | 1 |
| Cumming, JA; Hargreave, TB; Kirk, D; Newling, DW; Whelan, P | 1 |
| Blom, J; Carpentier, PJ; Groen, JM; Krueger, CG; Kurth, KH; Mross, K; ten Kate, F; van Aubel, O; van Caubergh, RD; Weissglas, G | 1 |
| Damianov, Kh; Patrashkov, T; Petkov, Ts; Petrov, P; Tonchev, T | 1 |
| Bub, P; Eisenberger, F; Jipp, P; Lüthgens, M; Rassweiler, J; Rüther, U | 1 |
| Donovski, L; Kumanov, Kh; Ormanov, I; Tsvetkov, M | 1 |
| Kumanov, Kh; Ormanov, I; Tsvetkov, M | 1 |
| da Silva, FC | 1 |
| Damionov, C; Petkov, T | 1 |
| Calciati, A; de Pauw, M; Fosså, SD; Pavone-Macaluso, M; Roozendaal, KJ; Splinter, T; Sylvester, R; Veenhof, KH | 1 |
| Alling, DW; Banks, SM; Dardir, MD; el-Aasar, AB; el-Grindy, MS; el-Mawla, NG; el-Zawahry, HM; Ferrans, VJ; Mikhael, YS | 1 |
| Burk, K; Kurth, KH; Newling, D | 1 |
| Bacchetti, P; Corrado, G; De Santis, P; Garofalo, F; Lelli, G; Maver, P; Pannuti, F; Tononi, A | 1 |
| Bäuerle, K; Bub, P; Eisenberger, F; Jipp, P; Rassweiler, J; Rüther, U | 1 |
| Cersosimo, RJ; Hong, WK | 1 |
| Groos, E; Masters, JR | 1 |
| Groos, E; Masters, JR; Walker, L | 1 |
| Bollack, C; Bono, A; Bouffioux, C; Calais da Silva, F; Denis, L | 1 |
| Akaza, H; Isaka, S; Ishikawa, H; Koiso, K; Koyanagi, T; Maru, A; Niijima, T; Sakashita, S; Shimazaki, J; Uchida, K | 1 |
| Bogdanowicz, JF; Kurth, KH; Maessen, P; Mross, K; Pinedo, HM; van der Vijgh, WJ | 1 |
| Tsushima, T | 1 |
| Akagi, T; Matsumura, Y; Nasu, Y; Obama, T; Ohmori, H; Ozaki, Y; Tsushima, T | 1 |
24 review(s) available for epirubicin and Bladder Cancer
| Article | Year |
|---|---|
Comparison Between Intravesical Chemotherapy Epirubicin and Mitomycin-C after TURB vs TURB Alone With Recurrence Rate of Non-Muscle Invasive Bladder Cancer: Meta-Analysis.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Epirubicin; Female; Humans; Male; Mitomycin; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms | 2022 |
Super-selective transcatheter vesical arterial chemoembolization with drug-loaded beads for muscle-invasive bladder cancer with hematuria.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Epirubicin; Hematuria; Humans; Liver Neoplasms; Muscles; Quality of Life; Retrospective Studies; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2023 |
Chemoablation in Urothelial Carcinoma: A Systematic Review and Future Perspectives.
Topics: Administration, Intravesical; Antineoplastic Agents; Aziridines; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Cystoscopy; Deoxycytidine; Epirubicin; Ethanol; Forecasting; Gemcitabine; Humans; Indolequinones; Injections, Intralesional; Interferon-alpha; Interleukin-2; Mitomycin; Urinary Bladder Neoplasms; Urothelium | 2020 |
Long-term versus short-term introvesical chemotherapy in patients with non-muscle-invasive bladder cancer: a systematic review and meta-analysis of the published results of randomized clinical trials.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Drug Therapy; Epirubicin; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2014 |
Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Disease Progression; Doxorubicin; Epirubicin; Humans; Mitomycin; Neoplasm Recurrence, Local; Neoplasm Staging; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Thiotepa; Time Factors; Urinary Bladder Neoplasms | 2016 |
Single, immediate postoperative instillation of chemotherapy in non-muscle invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials using different drugs.
Topics: Administration, Intravesical; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cyclophosphamide; Doxorubicin; Epirubicin; Humans; Melphalan; Network Meta-Analysis; Semustine; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; BCG Vaccine; Deoxycytidine; Disease Progression; Epirubicin; Female; Gemcitabine; Humans; Isoniazid; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Odds Ratio; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Assessing the Feasibility of Replacing Standard-Dose Bacillus Calmette-Guérin Immunotherapy with Other Intravesical Instillation Therapies in Bladder Cancer Patients: A Network Meta-Analysis.
Topics: Epirubicin; Female; Humans; Immunotherapy; Male; Mitomycin; Mycobacterium bovis; Urinary Bladder Neoplasms | 2017 |
Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Combined Modality Therapy; Epirubicin; Humans; Immunotherapy; Meta-Analysis as Topic; Mitomycin; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms | 2010 |
Ciprofloxacin criteria in antimicrobial prophylaxis and bladder cancer recurrence.
Topics: Anti-Infective Agents; Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Line, Tumor; Ciprofloxacin; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Epirubicin; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2010 |
Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Epirubicin; Humans; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms | 2011 |
[A case report of a young patient with invasive bladder cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Epirubicin; Humans; Male; Methotrexate; Neoplasm Invasiveness; Prostatic Neoplasms; Urinary Bladder Neoplasms; Urinary Diversion | 2003 |
Bladder cancer: current optimal intravesical treatment.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Cystectomy; Doxorubicin; Drug Administration Schedule; Epirubicin; Humans; Interferon-alpha; Mitomycin; Neoplasm Recurrence, Local; Nurse's Role; Patient Selection; Risk Factors; Salvage Therapy; Survival Rate; Thiotepa; Treatment Failure; United States; Urinary Bladder Neoplasms | 2005 |
Current views on intravesical treatment and chemoprophylaxis of superficial bladder cancer. The present role of epirubicin and doxorubicin.
Topics: Administration, Intravesical; Carcinoma in Situ; Doxorubicin; Epirubicin; Humans; Male; Urinary Bladder Neoplasms | 1993 |
Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Transitional Cell; Doxorubicin; Epirubicin; Female; Humans; Male; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Risk; Time Factors; Urinary Bladder Neoplasms | 1999 |
Improved patient outcomes with BCG immunotherapy vs. chemotherapy - Swedish and worldwide experience.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Chemotherapy, Adjuvant; Combined Modality Therapy; Doxorubicin; Epirubicin; Humans; Mitomycin; Sweden; Thiotepa; Treatment Outcome; Urinary Bladder Neoplasms | 2000 |
Epirubicin: a review of its intravesical use in superficial bladder cancer.
Topics: Antibiotics, Antineoplastic; Epirubicin; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms | 1999 |
Intravesical therapy of superficial bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; Doxorubicin; Epirubicin; Humans; Immunotherapy; Interferons; Mitomycin; Mitoxantrone; Mycobacterium bovis; Thiotepa; Urinary Bladder Neoplasms | 2000 |
An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy.
Topics: Administration, Intravesical; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Clinical Trials as Topic; Combined Modality Therapy; Doxorubicin; Epirubicin; Ethoglucid; Humans; Immunotherapy; Mitomycin; Thiotepa; Urinary Bladder Neoplasms | 2000 |
Intravesical therapy for superficial bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Anticarcinogenic Agents; Antineoplastic Agents; Carcinoma, Transitional Cell; Doxorubicin; Epirubicin; Humans; Interferons; Mitomycin; Mycobacterium bovis; Neoplasm, Residual; Photochemotherapy; Photosensitizing Agents; Thiotepa; Urinary Bladder Neoplasms | 2000 |
Complications of intravesical chemotherapy.
Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma, Transitional Cell; Doxorubicin; Epirubicin; Ethoglucid; Humans; Mitomycin; Mitoxantrone; Thiotepa; Urinary Bladder Neoplasms | 1992 |
The role of adriamycin and epirubicin in superficial bladder cancer and carcinoma in situ.
Topics: Carcinoma in Situ; Carcinoma, Papillary; Carcinoma, Transitional Cell; Clinical Trials as Topic; Doxorubicin; Epirubicin; Europe; Female; Humans; Male; Multicenter Studies as Topic; Urinary Bladder Neoplasms | 1989 |
[Immunochemotherapy of advanced bladder tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Cisplatin; Cyclophosphamide; Epirubicin; Humans; Immunotherapy; Male; Middle Aged; Postoperative Period; Urinary Bladder Neoplasms | 1989 |
Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue.
Topics: Bone Marrow; Breast Neoplasms; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colonic Neoplasms; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Epirubicin; Female; Head and Neck Neoplasms; Heart; Humans; Kidney Neoplasms; Kinetics; Leukemia; Liver Neoplasms; Lung Neoplasms; Lymphoma; Male; Melanoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms; Soft Tissue Neoplasms; Stomach Neoplasms; Urinary Bladder Neoplasms | 1986 |
113 trial(s) available for epirubicin and Bladder Cancer
| Article | Year |
|---|---|
Single Versus Maintenance Intravesical Chemotherapy for the Prevention of Bladder Recurrence after Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Randomized Clinical Trial.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Drug Administration Schedule; Epirubicin; Female; Humans; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Nephroureterectomy; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2019 |
The value of immediate postoperative intravesical epirubicin instillation as an adjunct to standard adjuvant treatment in intermediate and high-risk non-muscle-invasive bladder cancer: A preliminary results of randomized controlled trial.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Cystectomy; Cystoscopy; Disease Progression; Epirubicin; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Postoperative Care; Progression-Free Survival; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms; Young Adult | 2019 |
Evaluation of the effects of intra-arterial chemotherapy combined with intravesical chemotherapy against intravesical chemotherapy alone after transurethral resection of bladder tumor in T1-staged Grade 3 bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Epirubicin; Female; Follow-Up Studies; Humans; Injections, Intra-Arterial; Male; Middle Aged; Muscle Neoplasms; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Rate; Urinary Bladder Neoplasms | 2019 |
Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Drug Therapy, Combination; Epirubicin; Female; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Recurrence, Local; Organ Sparing Treatments; Pilot Projects; Prospective Studies; Survival Analysis; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2013 |
5-Year outcome of a randomized prospective study comparing bacillus Calmette-Guérin with epirubicin and interferon-α2b in patients with T1 bladder cancer.
Topics: Adjuvants, Immunologic; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Chemotherapy, Adjuvant; Epirubicin; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Neoplasm Staging; Prospective Studies; Recombinant Proteins; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2014 |
The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Topics: Age Factors; Aged; Aged, 80 and over; BCG Vaccine; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cystectomy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Proportional Hazards Models; Risk Assessment; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2014 |
Carboplatin, methotrexate, vinblastine, and epirubicin (M-VECa) as salvage treatment in patients with advanced bladder cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Survival Rate; Urinary Bladder Neoplasms; Vinblastine | 2015 |
Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Epirubicin; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Recombinant Proteins; Survival Analysis; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2016 |
[Intravesical instillation with epirubicin as a prophylactic treatment for superficial bladder cancer--using two different schedules].
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Cystectomy; Drug Administration Schedule; Epirubicin; Female; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Risk Factors; Urinary Bladder Neoplasms | 2008 |
Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Combined Modality Therapy; Epirubicin; Female; Humans; Male; Neoplasm Invasiveness; Postoperative Care; Prospective Studies; Time Factors; Urinary Bladder Neoplasms; Urologic Surgical Procedures | 2009 |
Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study.
Topics: Administration, Intravesical; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma; Chemotherapy, Adjuvant; Cystectomy; Disease Progression; Disease-Free Survival; Epirubicin; Female; Humans; Interferon alpha-2; Interferon-alpha; Kaplan-Meier Estimate; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Recombinant Proteins; Risk Assessment; Risk Factors; Scandinavian and Nordic Countries; Time Factors; Treatment Outcome; Tumor Burden; Urinary Bladder Neoplasms | 2010 |
Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Drug Therapy, Combination; Epirubicin; Humans; Isoniazid; Middle Aged; Neoplasm Staging; Risk Assessment; Time Factors; Urinary Bladder Neoplasms | 2010 |
Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: a prospective, randomized controlled study.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Humans; Male; Neoplasm Recurrence, Local; Prospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Surgical Procedures | 2010 |
A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Combined Modality Therapy; Cystoscopy; Epidemiologic Methods; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Treatment Outcome; Urinary Bladder Neoplasms | 2010 |
Intra-arterial chemotherapy is reliable in preventing high-risk superficial bladder cancer from recurrence and progression.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Disease Progression; Epirubicin; Female; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2009 |
Comparison of the efficacy of single or double intravesical epirubicin instillation in the early postoperative period to prevent recurrences in non-muscle-invasive urothelial carcinoma of the bladder: prospective, randomized multicenter study.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Postoperative Period; Recurrence; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2010 |
MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease Progression; DNA-Binding Proteins; Endonucleases; Epirubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Methotrexate; Middle Aged; Prognosis; Urinary Bladder Neoplasms; Vinblastine | 2010 |
Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Antineoplastic Agents; BCG Vaccine; Combined Modality Therapy; Cystectomy; Disease-Free Survival; Epidemiologic Methods; Epirubicin; Female; Humans; Male; Middle Aged; Mycobacterium bovis; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Treatment Outcome; Urinary Bladder Neoplasms; Young Adult | 2011 |
[Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer].
Topics: Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2011 |
Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Urinary Bladder Neoplasms | 2013 |
Neoadjuvant chemotherapy with sequential methotrexate and 5-fluorouracil scheduling, epirubicin and cisplatin for locally advanced bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Epirubicin; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Neoplasm Staging; Treatment Outcome; Urinary Bladder Neoplasms | 2002 |
Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study--FinnBladder III long-term results.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Combined Modality Therapy; Epirubicin; Female; Humans; Interferon-alpha; Male; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Prospective Studies; Urinary Bladder Neoplasms | 2002 |
Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Kidney Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2002 |
Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of a randomized trial with epirubicin comparing short-term versus long-term maintenance treatment.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Epirubicin; Female; Humans; Long-Term Care; Male; Urinary Bladder Neoplasms | 2002 |
Superficial bladder tumours: analysis of prognostic factors and construction of a predictive index.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma, Transitional Cell; Disease Progression; Doxorubicin; Epirubicin; Female; Humans; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Treatment Outcome; Urinary Bladder Neoplasms | 2003 |
A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Epirubicin; Female; Follow-Up Studies; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Time Factors; Urethra; Urinary Bladder Neoplasms | 2004 |
Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer--The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30mg/40m
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2004 |
Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Urinary Bladder Neoplasms | 2004 |
Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Disease Progression; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Multiple Primary; Survival Rate; Time Factors; Urinary Bladder Neoplasms | 2005 |
Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2005 |
Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Chi-Square Distribution; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Quality of Life; Risk Assessment; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2005 |
[Efficacy and safety of different dosages of intravesical epirubicin instillation for prevention of primary superficial bladder carcinoma from recurrence].
Topics: Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Combined Modality Therapy; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Postoperative Period; Prospective Studies; Urinary Bladder Neoplasms | 2005 |
Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cystectomy; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2006 |
Randomized study of single instillation of epirubicin for superficial bladder carcinoma: long-term clinical outcomes.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Epirubicin; Humans; Middle Aged; Neoplasm Recurrence, Local; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Cystectomy; Epirubicin; Female; Humans; Male; Neoplasm Recurrence, Local; Prospective Studies; Urethra; Urinary Bladder Neoplasms | 2008 |
Prevention of recurrence with epirubicin and lactobacillus casei after transurethral resection of bladder cancer.
Topics: Administration, Intravesical; Administration, Oral; Aged; Antibiotics, Antineoplastic; Cohort Studies; Combined Modality Therapy; Cystoscopy; Disease-Free Survival; Epirubicin; Female; Humans; Lacticaseibacillus casei; Male; Middle Aged; Neoplasm Recurrence, Local; Probiotics; Urinary Bladder Neoplasms | 2008 |
Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cystoscopy; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2008 |
Are prostate biopsies mandatory in patients with prostate-specific antigen increase during intravesical immuno- or chemotherapy for superficial bladder cancer?
Topics: Aged; Antibiotics, Antineoplastic; BCG Vaccine; Biopsy; Drug Monitoring; Epirubicin; Humans; Immunotherapy; Male; Middle Aged; Mitomycin; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatitis; Unnecessary Procedures; Urinary Bladder Neoplasms | 2008 |
Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vaccine; Double-Blind Method; Drug Synergism; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Invasiveness; Prospective Studies; Risk Factors; Time Factors; Urinary Bladder Neoplasms | 2008 |
M-VEC (methotrexate, vinblastine, epirubicin, and cisplatin) with granulocyte colony-stimulating factor for the treatment of urothelial cancer: an effective and safe chemotherapy regimen.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cisplatin; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Injections, Intravenous; Kidney Neoplasms; Kidney Pelvis; Lung Neoplasms; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Recombinant Proteins; Tomography, X-Ray Computed; Ureteral Neoplasms; Urinary Bladder Neoplasms; Vinblastine; World Health Organization | 1994 |
Adjuvant and neoadjuvant chemotherapy for invasive bladder cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Cystectomy; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Injections, Intravenous; Japan; Male; Methotrexate; Middle Aged; Survival Rate; Urinary Bladder Neoplasms; Vinblastine | 1994 |
[Prophylactic intra-arterial chemotherapy for CR patients with invasive bladder cancer after induction therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Urinary Bladder Neoplasms | 1995 |
[Intravesical instillation of epirubicin hydrochloride in superficial bladder tumor--prophylactic and therapeutic instillation for carcinoma in situ].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma in Situ; Cystitis; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Hemorrhage; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Urinary Bladder Neoplasms | 1995 |
[The role of M-VAC polychemotherapy in the treatment of advanced urothelial carcinoma of the bladder].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Doxorubicin; Epirubicin; Female; Humans; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Palliative Care; Remission Induction; Urinary Bladder Neoplasms; Vinblastine | 1993 |
[Neoadjuvant chemotherapy in advanced-stage bladder carcinoma. A randomized prospective study comparing MVAC and MVEEC].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cystectomy; Doxorubicin; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Prospective Studies; Urinary Bladder Neoplasms; Vinblastine | 1994 |
Combined immunochemotherapy (CEP, M-VEP + BCG) in the treatment of invasive bladder tumors.
Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Cisplatin; Combined Modality Therapy; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Immunotherapy, Active; Lomustine; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Prednimustine; Urinary Bladder Neoplasms; Vinblastine | 1994 |
Superficial bladder cancer: the response of a marker tumour to a single intravesical instillation of epirubicin.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Male; Middle Aged; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 1994 |
Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cystectomy; Doxorubicin; Epirubicin; Female; Humans; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Prospective Studies; Survival Rate; Urinary Bladder Neoplasms; Vinblastine | 1995 |
Results of adjuvant chemotherapy for invasive urothelial cancer with lymph-node metastasis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Kidney Pelvis; Longitudinal Studies; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Survival Rate; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 1994 |
A randomized trial of early intravesical instillation of epirubicin in superficial bladder cancer. The Nagoya University Urological Oncology Group.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cystoscopy; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 1994 |
Prophylactic chemotherapy with anthracyclines (adriamycin, epirubicin, and pirarubicin) for primary superficial bladder cancer. The Hokkaido University Bladder Cancer Collaborative Group.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Regression Analysis; Urinary Bladder Neoplasms | 1994 |
Prospective randomized study of prophylaxis of superficial bladder cancer with epirubicin: the role of a central pathology laboratory. Nara Uro-oncology Research Group. (NUORG).
Topics: Administration, Intravesical; Aged; Chemotherapy, Adjuvant; Epirubicin; Female; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasm Recurrence, Local; Pathology Department, Hospital; Prognosis; Prospective Studies; Urinary Bladder Neoplasms | 1994 |
Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial. Kobe University Urological Oncology Group.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Doxorubicin; Epirubicin; Female; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 1994 |
Phase II study of intravesical chemoprophylaxis of epirubicin after transurethral resection of bladder tumors. Tottori University Oncology Group.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Epirubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 1994 |
A phase II study of prophylactic intravesical chemotherapy with epirubicin in the treatment of superficial bladder cancer. Tokyo Women's Medical College Bladder Cancer Collaborating Group.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cystoscopy; Epirubicin; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 1994 |
A phase II study of prophylactic intravesical chemotherapy with 4'-epirubicin in recurrent superficial bladder cancer: comparison of 4'-epirubicin and adriamycin.
Topics: Administration, Intravesical; Adult; Aged; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 1994 |
The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin for prophylaxis of recurrence of superficial bladder cancer: a preliminary report.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Combined Modality Therapy; Epirubicin; Female; Follow-Up Studies; Humans; Immunotherapy; Longitudinal Studies; Male; Middle Aged; Mycobacterium bovis; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 1994 |
Correlation between clinical response and urinary interleukin levels using different doses and intravesical administration schedules of interferon-alpha-2b combined with epirubicin: a pilot study.
Topics: Administration, Intravesical; Combined Modality Therapy; Drug Administration Schedule; Epirubicin; Humans; Interferon alpha-2; Interferon-alpha; Interleukin-1; Interleukin-2; Interleukin-4; Interleukins; Neoplasm Recurrence, Local; Recombinant Proteins; Urinary Bladder Neoplasms | 1993 |
A plea for cold biopsy, fulguration and immediate bladder instillation with Epirubicin in small superficial bladder tumors. Data from the EORTC GU Group Study 30863.
Topics: Administration, Intravesical; Biopsy; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystoscopy; Epirubicin; Humans; Neoplasm Recurrence, Local; Neoplasm Seeding; Urinary Bladder Neoplasms | 1993 |
Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer.
Topics: Administration, Intravesical; Aged; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystitis; Epirubicin; Female; Follow-Up Studies; Humans; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Remission Induction; Urinary Bladder Neoplasms | 1993 |
A phase II study of epirubicin in advanced transitional cell bladder cancer. The Yorkshire Urological Cancer Research Group.
Topics: Carcinoma, Transitional Cell; Drug Administration Schedule; Epirubicin; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Urinary Bladder Neoplasms | 1993 |
A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinom
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Combined Modality Therapy; Epirubicin; Female; Follow-Up Studies; Humans; Male; Neoplasm Recurrence, Local; Prospective Studies; Time Factors; Urinary Bladder Neoplasms; Water | 1993 |
Carboplatin, methotrexate, vinblastine and epirubicin (Carbo-MVE) for transitional cell bladder carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Urinary Bladder Neoplasms; Vinblastine | 1993 |
A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Finnish Multicentre Study Group.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Neoplasm Recurrence, Local; Recombinant Proteins; Treatment Outcome; Urinary Bladder Neoplasms | 1995 |
Response to epirubicin in patients with superficial bladder cancer and expression of the topoisomerase II alpha and beta genes.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Transitional Cell; DNA Topoisomerases, Type II; Enzyme Inhibitors; Epirubicin; Female; Gene Expression Regulation, Neoplastic; Humans; Isoenzymes; Male; Middle Aged; Urinary Bladder Neoplasms | 1996 |
Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms; Vinblastine | 1996 |
Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1, G3 transitional cell carcinoma of the bladder.
Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Doxorubicin; Epirubicin; Follow-Up Studies; Humans; Mitomycins; Neoplasm Recurrence, Local; Neoplasm Staging; Surgical Procedures, Operative; Urethra; Urinary Bladder Neoplasms | 1996 |
Treatment of advanced urothelial carcinoma with M-VECA (methotrexate, vinblastine, epirubicin and carboplatin).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Urinary Bladder Neoplasms; Vinblastine | 1996 |
Chemoresection in Ta-T1 bladder cancer. Members of the EORTC Genito-Urinary Group.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Drug Administration Schedule; Epirubicin; Female; Humans; Male; Mitomycin; Treatment Outcome; Urinary Bladder Neoplasms | 1996 |
Intravesical instillation of epirubicin: effect on tumour recurrence in patients with dysplastic epithelium after transurethral resection of superficial bladder tumour.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Disease Progression; Disease-Free Survival; Epirubicin; Epithelium; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Risk Factors; Urinary Bladder Neoplasms | 1996 |
Intravesical epirubicin in the prophylaxis of superficial bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Combined Modality Therapy; Cystectomy; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 1996 |
BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumours: results of a prospective randomized study using modified treatment schemes.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Disease-Free Survival; Epirubicin; Female; Humans; Immunotherapy; Male; Neoplasm Recurrence, Local; Prospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 1996 |
Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Dose-Response Relationship, Drug; Epirubicin; Female; Follow-Up Studies; Humans; Infant, Newborn; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Urinary Bladder Neoplasms | 1997 |
Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Disease Progression; Doxorubicin; Epirubicin; Female; Humans; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Urinary Bladder Neoplasms | 1997 |
Chemotherapy with methotrexate, vinblastine, epirubicin and carboplatin (Carbo-MVE) in transitional cell urothelial cancer. A Hellenic Co-Operative Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystectomy; Disease Progression; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Treatment Outcome; Urethral Neoplasms; Urinary Bladder Neoplasms; Vinblastine; World Health Organization | 1997 |
[Clinical efficacy of post-TUR prophylactic chemotherapy for superficial bladder cancer--the result of co-operative prospective randomized trial].
Topics: Administration, Intravesical; Administration, Oral; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cystectomy; Epirubicin; Fluorouracil; Humans; Neoplasm Recurrence, Local; Postoperative Care; Prospective Studies; Urinary Bladder Neoplasms | 1997 |
Neoadjuvant treatment of cancer of the bladder with M-VAC/M-VEC, and bladder-sparing policy: preliminary report of a non-randomized study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease Progression; Doxorubicin; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Survival Analysis; Urinary Bladder Neoplasms; Vinblastine | 1996 |
A randomized study of short-versus long-term intravesical epirubicin instillation for superficial bladder cancer. Nagoya University Urological Oncology Group.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Drug Administration Schedule; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Urinary Bladder Neoplasms | 1998 |
Absorption of epirubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer.
Topics: Absorption; Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Epirubicin; Humans; Male; Middle Aged; Neoplasm Staging; Postoperative Period; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Surgical Procedures | 1998 |
[Results of clinical study with epirubicin hydrochloride injectable solution for superficial bladder cancer. IMI28 Injectable Solution Study Group for Superficial Bladder Cancer].
Topics: Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Drug Administration Schedule; Epirubicin; Female; Hematuria; Humans; Male; Middle Aged; Urinary Bladder Neoplasms; Urination Disorders | 1998 |
Transurethral resection with perioperative instilation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study--Finnbladder III.
Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma, Transitional Cell; Combined Modality Therapy; Epirubicin; Female; Humans; Interferon-alpha; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Urinary Bladder Neoplasms | 1999 |
Intravesical chemotherapy with epirubicin: a dose response study.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 1999 |
[Intra-arterial chemotherapy for locally advanced bladder cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Humans; Infusions, Intra-Arterial; Male; Radiotherapy Dosage; Survival Rate; Urinary Bladder Neoplasms | 1999 |
Analysis of prognostic factors related to primary superficial bladder cancer tumor recurrence in prophylactic intravesical epirubicin therapy.
Topics: Administration, Intravesical; Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Combined Modality Therapy; Epirubicin; Female; Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Risk Factors; Secondary Prevention; Urinary Bladder Neoplasms | 1999 |
[Effect of prophylactic treatment with intravesical epirubicin in recurrence of superficial bladder tumor].
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Epirubicin; Humans; Middle Aged; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 1999 |
Sequential bacillus Calmette-Guerin and epirubicin versus bacillus Calmette-Guerin alone for superficial bladder tumors: a randomized prospective study.
Topics: Adjuvants, Immunologic; Adult; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Drug Therapy, Combination; Epirubicin; Female; Humans; Male; Middle Aged; Prospective Studies; Urinary Bladder Neoplasms | 1999 |
Investigating centre effects in a multi-centre clinical trial of superficial bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Epirubicin; Humans; Likelihood Functions; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Proportional Hazards Models; Time Factors; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 1999 |
Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Docetaxel; Epirubicin; Female; Humans; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Urinary Bladder Neoplasms | 2000 |
Transurethral resection and sequential chemo-immunoprophylaxis in primary T1G3 bladder cancer.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystectomy; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Humans; Immunotherapy; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2000 |
Cytological changes induced by intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Case-Control Studies; Epirubicin; Female; Humans; Male; Middle Aged; Urinary Bladder; Urinary Bladder Neoplasms | 2000 |
Clinical experience with BCG alone versus BCG plus epirubicin.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Combined Modality Therapy; Epirubicin; Female; Follow-Up Studies; Humans; Immunotherapy; Male; Middle Aged; Mycobacterium bovis; Neoplasm Recurrence, Local; Treatment Outcome; Urinary Bladder Neoplasms | 2000 |
[Continuous intravesical instillation of epirubicin immediately after transurethral resection of superficial bladder cancer: a prospective controlled study].
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Perioperative Care; Premedication; Prospective Studies; Therapeutic Irrigation; Urinary Bladder Neoplasms | 2000 |
Alpha 2-b interferon and farmarubicin in the prophylaxis of recurrence of superficial transitional cell carcinoma of the urinary bladder.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Epirubicin; Humans; Interferon alpha-2; Interferon-alpha; Neoplasm Recurrence, Local; Recombinant Proteins; Urinary Bladder Neoplasms | 2000 |
High-dose epirubicin in the prophylactic treatment of T1G2 superficial bladder tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Staging; Urinary Bladder Neoplasms | 2001 |
Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-uri
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Papillary; Drug Therapy, Combination; Epirubicin; Female; Humans; Isoniazid; Male; Middle Aged; Urinary Bladder Neoplasms | 2001 |
[Intravesical instillation of doxorubicin or epirubicin for chemoprophylaxis of superficial bladder cancer--the fifth study of the Japanese Urological Cancer Research Group for Adriamycin/Farumorubicin].
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Epirubicin; Female; Humans; Instillation, Drug; Male; Neoplasm Recurrence, Local; Postoperative Care; Urinary Bladder Neoplasms | 2002 |
[Single instillation of epirubicin for the prophylaxis of recurrent primary superficial bladder carcinoma].
Topics: Aged; Antibiotics, Antineoplastic; Epirubicin; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2002 |
Delayed high-dose intravesical epirubicin therapy of superficial bladder cancer. A way to reduce the side effects and increase the efficacy--a phase 2 trial.
Topics: Administration, Intravesical; Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Delayed-Action Preparations; Epirubicin; Female; Humans; Male; Middle Aged; Time Factors; Urinary Bladder Neoplasms | 2002 |
Intravesical instillation of adriamycin for bladder tumors.
Topics: Administration, Intravesical; Carcinoma, Papillary; Clinical Trials as Topic; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Epirubicin; Humans; Time Factors; Urinary Bladder Neoplasms | 1992 |
Intravesical therapy with adriamycin and 4-epirubicin for superficial bladder cancer: the experience of the EORTC GU Group.
Topics: Administration, Intravesical; Chemotherapy, Adjuvant; Doxorubicin; Epirubicin; Ethoglucid; Humans; Neoplasm Recurrence, Local; Prospective Studies; Urinary Bladder Neoplasms | 1992 |
Chemotherapy with cisplatin, epirubicin, methotrexate in the treatment of locally advanced or metastatic transitional cell cancer of the bladder (TCC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Creatinine; Drug Administration Schedule; Epirubicin; Female; Humans; Male; Metabolic Clearance Rate; Methotrexate; Middle Aged; Urinary Bladder Neoplasms | 1992 |
Phase I-II pilot study on the efficacy and tolerability of neoadjuvant chemotherapy (Rescue M-VEC) and preoperative radiation therapy for infiltrating bladder cancer: results of an 18-month follow-up.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Cystectomy; Epirubicin; Evaluation Studies as Topic; Female; Humans; Male; Methotrexate; Middle Aged; Pilot Projects; Preoperative Care; Radioisotope Teletherapy; Remission Induction; Urinary Bladder Neoplasms; Vinblastine | 1992 |
4'-epidoxorubicin versus mitomycin C intravesical chemoprophylaxis of superficial bladder cancer.
Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Epirubicin; Female; Follow-Up Studies; Humans; Male; Mitomycin; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 1992 |
Chemoimmunotherapy for prophylaxis of recurrence in superficial bladder cancer: interferon-alpha 2b versus interferon-alpha 2b with epirubicin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Neoplasm Recurrence, Local; Recombinant Proteins; Urinary Bladder Neoplasms | 1992 |
Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Prospective Studies; Survival Rate; Urinary Bladder Neoplasms; Vinblastine | 1992 |
Intravesical instillations of 4-epi-doxorubicin (epirubicin) in the prophylactic treatment of superficial bladder cancer: results of a controlled prospective study.
Topics: Administration, Intravesical; Aged; Carcinoma, Transitional Cell; Epirubicin; Female; Humans; Male; Neoplasm Recurrence, Local; Prospective Studies; Urinary Bladder Neoplasms | 1992 |
Intravesical epirubicin with and without verapamil for the prophylaxis of superficial bladder tumours.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Drug Synergism; Electrocoagulation; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms; Verapamil | 1991 |
A randomized pilot study of high-dose epirubicin as neoadjuvant chemotherapy in the treatment of cancer of the bilharzial bladder.
Topics: Adult; Carcinoma; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Combined Modality Therapy; Epirubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Postoperative Complications; Schistosomiasis; Survival Rate; Urinary Bladder Neoplasms | 1991 |
Multi-centre phase II study of low dose intravesical epirubicin in the treatment of superficial bladder cancer. Yorkshire and Scottish Urological Cancer Research Groups.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Urinary Bladder Neoplasms | 1991 |
A multi-centre phase two study of intravesical epirubicin in the treatment of superficial bladder tumour.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Epirubicin; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Urinary Bladder Neoplasms | 1990 |
The role of adriamycin and epirubicin in superficial bladder cancer and carcinoma in situ.
Topics: Carcinoma in Situ; Carcinoma, Papillary; Carcinoma, Transitional Cell; Clinical Trials as Topic; Doxorubicin; Epirubicin; Europe; Female; Humans; Male; Multicenter Studies as Topic; Urinary Bladder Neoplasms | 1989 |
Intravesical chemoresection with 4'-epi-doxorubicin in patients with superficial bladder tumors.
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Clinical Trials as Topic; Combined Modality Therapy; Cystoscopy; Doxorubicin; Epirubicin; Female; Humans; Male; Middle Aged; Stereoisomerism; Urinary Bladder Neoplasms | 1988 |
[Intravesical chemotherapy with 4'-EPI-adriamycin in patients with superficial bladder tumors (randomized study)].
Topics: Adult; Aged; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Humans; Male; Middle Aged; Random Allocation; Urinary Bladder; Urinary Bladder Neoplasms | 1985 |
172 other study(ies) available for epirubicin and Bladder Cancer
| Article | Year |
|---|---|
Development of Novel Aptamer-Based Targeted Chemotherapy for Bladder Cancer.
Topics: Administration, Intravesical; Animals; Epirubicin; Humans; Mice; Quality of Life; Urinary Bladder Neoplasms; Urothelium | 2022 |
[Intravesical adjuvant regimen of epitubicin for intermediate risk NMIBC: Feasability study from CC-AFU vessie].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Clinical Protocols; COVID-19 Drug Treatment; Epirubicin; Female; Humans; Male; Mitomycin; Neoplasm Invasiveness; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
[Guidelines from the cancer committee of the French Association of Urology (CC-AFU) for adequate intravesical instillations of Mitomycin C, Epirubicin, and BCG for non-muscle invasive bladder cancer].
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Epirubicin; Female; Humans; Male; Mitomycin; Neoplasm Invasiveness; Urinary Bladder Neoplasms; Urology | 2022 |
Molecular classification of patients with NMIBC predicts the efficacy of intravesical chemotherapy with pirarubicin, pharmorubicin and gemcitabine-immunohistochemistry-based classification.
Topics: Administration, Intravesical; Anthracyclines; Antibiotics, Antineoplastic; Deoxycytidine; Doxorubicin; Epirubicin; Gemcitabine; Humans; Immunohistochemistry; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2022 |
Bladder cancer selective chemotherapy with potent NQO1 substrate co-loaded prodrug nanoparticles.
Topics: Administration, Intravesical; Epirubicin; Humans; NAD(P)H Dehydrogenase (Quinone); Nanoparticles; Prodrugs; Reactive Oxygen Species; Urinary Bladder Neoplasms | 2022 |
Mannose-targeting Concanavalin A-Epirubicin Conjugate for Targeted Intravesical Chemotherapy of Bladder Cancer.
Topics: Administration, Intravesical; Animals; Antibiotics, Antineoplastic; Concanavalin A; Epirubicin; Humans; Mannose; Mice; Urinary Bladder Neoplasms | 2022 |
Atezolizumab for the treatment of advanced recurrent basal cell carcinoma and urothelial carcinoma of bladder: a case report.
Topics: Aged; Antibodies, Monoclonal; Carcinoma, Basal Cell; Carcinoma, Transitional Cell; COVID-19; Epirubicin; Female; Humans; Immune Checkpoint Inhibitors; Skin Neoplasms; Urinary Bladder; Urinary Bladder Neoplasms | 2022 |
Evaluation of thermal dose effect in radiofrequency-induced hyperthermia with intravesical chemotherapy for nonmuscle invasive bladder cancer.
Topics: Combined Modality Therapy; Epirubicin; Humans; Hyperthermia, Induced; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2023 |
Long-term prevention of bladder cancer progression by alpha1-oleate alone or in combination with chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Epirubicin; Mice; Mitomycin; Neoplasm Recurrence, Local; Oleic Acid; Urinary Bladder; Urinary Bladder Neoplasms | 2023 |
Comparison of gemcitabine and anthracycline antibiotics in prevention of superficial bladder cancer recurrence.
Topics: Aged; Anthracyclines; Antineoplastic Agents; Deoxycytidine; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2019 |
Transurethral holmium laser resection and transurethral electrocision combined with intravesical epirubicin within 24 hours postoperatively for treatment of bladder cancer.
Topics: Aged; Antibiotics, Antineoplastic; China; Combined Modality Therapy; Epirubicin; Female; Humans; Laser Therapy; Lasers, Solid-State; Male; Middle Aged; Operative Time; Postoperative Period; Prospective Studies; Survival Rate; Urinary Bladder Neoplasms; Urologic Surgical Procedures | 2020 |
The Apoptosis Mechanism of Epirubicin Combined with BCG on Human Bladder Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; BCG Vaccine; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Epirubicin; Humans; Molecular Structure; Structure-Activity Relationship; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2020 |
Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cystectomy; Doxorubicin; Epirubicin; Female; Humans; Immunotherapy; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Invasiveness; Retrospective Studies; Risk Factors; Urinary Bladder Neoplasms | 2021 |
Impact of immunohistochemistry-based molecular subtype on predicting chemotherapy response and survival in patients with T1 stage bladder cancer after bladder-preserving treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Staging; Organ Sparing Treatments; Prognosis; Progression-Free Survival; Treatment Outcome; Urinary Bladder Neoplasms | 2021 |
Epirubicin-induced Kounis syndrome.
Topics: Antibiotics, Antineoplastic; Epirubicin; Humans; Iliac Artery; Injections, Intra-Arterial; Kounis Syndrome; Male; Middle Aged; Treatment Outcome; Urinary Bladder Neoplasms | 2021 |
Epithelial-mesenchymal transition induced by GRO-α-CXCR2 promotes bladder cancer recurrence after intravesical chemotherapy.
Topics: Administration, Intravesical; Animals; Chemokine CXCL1; Epirubicin; Epithelial-Mesenchymal Transition; Female; HEK293 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Recurrence, Local; Random Allocation; Receptors, Interleukin-8B; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Toward Better Predictions of Chemosensitivity: Comparative Study of Conventional and Simulated Chemosensitivity Tests for Bladder Cancer Cell Lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Docetaxel; Epirubicin; Gemcitabine; Humans; Mitomycin; Urinary Bladder Neoplasms | 2017 |
[The mechanism underlying the effects of tea polyphenol on epirubicin-induced autophagy and apoptosis in T24 bladder cancer cells].
Topics: Antibiotics, Antineoplastic; Apoptosis; Autophagy; Cell Line, Tumor; Epirubicin; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Polyphenols; Tea; Urinary Bladder Neoplasms | 2017 |
Update on the role of endovesical chemotherapy in nonmuscle-invasive bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Combined Modality Therapy; Doxorubicin; Epirubicin; Humans; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Practice Guidelines as Topic; Urinary Bladder Neoplasms | 2018 |
MicroRNA-34a Attenuates Metastasis and Chemoresistance of Bladder Cancer Cells by Targeting the TCF1/LEF1 Axis.
Topics: 3' Untranslated Regions; Animals; Antagomirs; Apoptosis; Cell Line, Tumor; Databases, Genetic; Down-Regulation; Drug Resistance, Neoplasm; Epirubicin; G1 Phase Cell Cycle Checkpoints; Hepatocyte Nuclear Factor 1-alpha; Humans; Kaplan-Meier Estimate; Lymphoid Enhancer-Binding Factor 1; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neoplasm Metastasis; Urinary Bladder Neoplasms | 2018 |
Efficacy of intra-arterial chemotherapy combined with intravesical chemotherapy in T1G3 bladder cancer when compared with intravesical chemotherapy alone after bladder-sparing surgery: a retrospective study.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystoscopy; Doxorubicin; Epirubicin; Female; Humans; Injections, Intra-Arterial; Male; Middle Aged; Neoplasm Recurrence, Local; Organ Sparing Treatments; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2019 |
Gradiently degraded electrospun polyester scaffolds with cytostatic for urothelial carcinoma therapy.
Topics: Animals; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Liberation; Epirubicin; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Polyesters; Polylactic Acid-Polyglycolic Acid Copolymer; Proto-Oncogene Proteins c-bcl-2; Transplantation, Heterologous; Urinary Bladder Neoplasms | 2019 |
Magnetic multiwalled carbon nanotubes with controlled release of epirubicin: an intravesical instillation system for bladder cancer.
Topics: Administration, Intravesical; Animals; Antibiotics, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Delayed-Action Preparations; Epirubicin; Female; Humans; Ki-67 Antigen; Magnetics; Male; Nanotubes, Carbon; Rats; Urinary Bladder Neoplasms | 2019 |
Intra-arterial chemotherapy combined with intravesical chemotherapy is effective in preventing recurrence in non-muscle invasive bladder cancer.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Cystectomy; Epirubicin; Female; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Urinary Bladder Neoplasms | 2019 |
The investigation of a traditional Chinese medicine, Guizhi Fuling Wan (GFW) as an intravesical therapeutic agent for urothelial carcinoma of the bladder.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 2; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Drugs, Chinese Herbal; Epirubicin; Humans; Mitomycin; Phytotherapy; Protein Serine-Threonine Kinases; Sincalide; Urinary Bladder; Urinary Bladder Neoplasms; Urothelium | 2013 |
[Efficacy and safety of maintenance intravesical instillation therapy with bacillus Calmette-Guerin and epirubicin for non-muscle invasive bladder cancer].
Topics: Administration, Intravesical; Adult; Aged; BCG Vaccine; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
The effect of photochemical internalization of bleomycin in the treatment of urothelial carcinoma of the bladder: an in vitro study.
Topics: Animals; Antibiotics, Antineoplastic; Bleomycin; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Epirubicin; Gemcitabine; Humans; Light; Mitomycin; Photochemotherapy; Photosensitizing Agents; Porphyrins; Rats; Time Factors; Urinary Bladder Neoplasms | 2014 |
Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Female; Humans; Hyperthermia, Induced; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Prospective Studies; Time Factors; Urinary Bladder Neoplasms | 2014 |
[Treatment and prognosis of 117 patients with advanced urothelial carcinoma of the bladder].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate; Thrombocytopenia; Urinary Bladder Neoplasms; Urothelium | 2014 |
[A case of effective neoadjuvant chemotherapy (MVEC) against right ureteral cancer involving bladder (cT4N1M0)].
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin; Epirubicin; Humans; Male; Methotrexate; Neoadjuvant Therapy; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms; Vinblastine | 2014 |
Predicting response to bacillus Calmette-Guérin: time to look beyond the ages.
Topics: BCG Vaccine; Carcinoma, Transitional Cell; Epirubicin; Female; Humans; Male; Urinary Bladder Neoplasms | 2014 |
High-dose chemotherapeutics of intravesical chemotherapy rapidly induce mitochondrial dysfunction in bladder cancer-derived spheroids.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; DNA Fragmentation; Epirubicin; Humans; Male; Membrane Potential, Mitochondrial; Mice, Inbred NOD; Mice, SCID; Mitochondria; Mitomycin; Neoplasm Transplantation; Spheroids, Cellular; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2015 |
Synergistic induction of apoptosis by mapatumumab and anthracyclines in human bladder cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Epirubicin; Gene Expression Regulation, Neoplastic; Humans; Receptors, TNF-Related Apoptosis-Inducing Ligand; Urinary Bladder Neoplasms | 2015 |
XRCC1 polymorphisms associated with survival among Chinese bladder cancer patients receiving epirubicin and mitomycin C.
Topics: Aged; Alleles; Biomarkers, Pharmacological; China; Disease-Free Survival; DNA-Binding Proteins; Epirubicin; Female; Genetic Association Studies; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Mitomycin; Polymorphism, Single Nucleotide; Urinary Bladder Neoplasms; X-ray Repair Cross Complementing Protein 1 | 2015 |
Ablative Intravesical Chemotherapy for Small Recurrent Non-Muscle-Invasive Bladder Cancer: A Prospective Study.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Combined Modality Therapy; Cystoscopy; Disease-Free Survival; Epirubicin; Female; Humans; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
The use of water-soluble mucoadhesive gels for the intravesical delivery of epirubicin to the bladder for the treatment of non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Animals; Antibiotics, Antineoplastic; Cellulose; Drug Carriers; Drug Delivery Systems; Epirubicin; Gels; Hypromellose Derivatives; Rheology; Solubility; Swine; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms; Viscosity; Water | 2015 |
Analysis of Japanese Patients Treated with or without Long-Term Epirubicin Plus Ara-C Intravesical Instillation Therapy for Low-Grade Superficial Bladder Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Epirubicin; Female; Follow-Up Studies; Humans; Japan; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Treatment Outcome; Urinary Bladder Neoplasms | 2015 |
Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystectomy; Cystoscopy; Disease Progression; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Humans; Japan; Male; Middle Aged; Natural Orifice Endoscopic Surgery; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome; Urethra; Urinary Bladder Neoplasms | 2015 |
Decreased Overall and Bladder Cancer-Specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Epirubicin; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Methotrexate; Neoadjuvant Therapy; Risk Assessment; Survival Rate; Urinary Bladder Neoplasms; Vinblastine | 2016 |
GSTP1 and GSTO1 single nucleotide polymorphisms and the response of bladder cancer patients to intravesical chemotherapy.
Topics: Administration, Intravesical; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Genotype; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitomycin; Neoplasm Grading; Polymorphism, Single Nucleotide; Retrospective Studies; Treatment Outcome; Tumor Burden; Urinary Bladder Neoplasms | 2015 |
Icaritin acts synergistically with epirubicin to suppress bladder cancer growth through inhibition of autophagy.
Topics: Autophagy; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Epirubicin; Flavonoids; HEK293 Cells; Humans; Membrane Potential, Mitochondrial; Time Factors; Urinary Bladder Neoplasms | 2016 |
RON Nuclear Translocation under Hypoxia Potentiates Chemoresistance to DNA Double-Strand Break-Inducing Anticancer Drugs.
Topics: Antigens, Nuclear; Cell Hypoxia; Cell Line, Tumor; Cell Nucleus; DNA End-Joining Repair; DNA-Activated Protein Kinase; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Epirubicin; Gene Knockdown Techniques; HEK293 Cells; Humans; Ku Autoantigen; Nuclear Proteins; Protein Transport; Receptor Protein-Tyrosine Kinases; Tandem Mass Spectrometry; Urinary Bladder Neoplasms | 2016 |
A Hydrogel-Based Epirubicin Delivery System for Intravesical Chemotherapy.
Topics: Administration, Intravesical; Animals; Antibiotics, Antineoplastic; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Epirubicin; Epithelium; Hydrogel, Polyethylene Glycol Dimethacrylate; Permeability; Rats; Signal Transduction; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Berberine promotes antiproliferative effects of epirubicin in T24 bladder cancer cells by enhancing apoptosis and cell cycle arrest
.
Topics: Antibiotics, Antineoplastic; Apoptosis; Berberine; Blotting, Western; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Epirubicin; Humans; Reactive Oxygen Species; Urinary Bladder Neoplasms | 2017 |
Re: Intravesical Bacillus Calmette-Guérin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Bacillus; BCG Vaccine; Epirubicin; Humans; Neoplasm Recurrence, Local; Urinary Bladder; Urinary Bladder Neoplasms | 2017 |
Intravesical chemotherapy use after radical nephroureterectomy: A national survey of urologic oncologists.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Doxorubicin; Epirubicin; Humans; Instillation, Drug; Kidney Neoplasms; Mitomycin; Neoplasm Recurrence, Local; Nephroureterectomy; Oncologists; Perioperative Care; Retrospective Studies; Surveys and Questionnaires; Thiotepa; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2017 |
Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to Epirubicin by promoting G1/S arrest and apoptosis.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epirubicin; G1 Phase; Humans; Receptor Protein-Tyrosine Kinases; S Phase; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2017 |
Feasibility of early intravesical instillation chemotherapy after transurethral resection of the bladder: a prospective evaluation in a consecutive series of 210 cases.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Biopsy; Chemotherapy, Adjuvant; Cystectomy; Cystoscopy; Dose-Response Relationship, Drug; Epirubicin; Female; Follow-Up Studies; Humans; Incidence; Instillation, Drug; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Postoperative Care; Prospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Young Adult | 2008 |
Re: A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences: I. Berrum-svennung, T. Granfors, S. Jahnson, H. Boman and S. Holmang. J Urol 2008; 179: 101-106.
Topics: Administration, Intravesical; Cystectomy; Cystoscopy; Dose-Response Relationship, Drug; Epirubicin; Female; Follow-Up Studies; Humans; Male; Neoplasm Recurrence, Local; Postoperative Care; Risk Assessment; Treatment Outcome; Urinary Bladder Neoplasms | 2008 |
Re: Can early single dose instillation of epirubicin improve bacillus calmette-guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study: T. Cai, G. Nesi, G. Tinacci
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Double-Blind Method; Drug Synergism; Epirubicin; Humans; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Urinary Bladder Neoplasms | 2009 |
Perioperative intravesical therapy: effective treatment, unfulfilled promises.
Topics: Antibiotics, Antineoplastic; Combined Modality Therapy; Epirubicin; Humans; Postoperative Care; Treatment Outcome; Urinary Bladder Neoplasms | 2009 |
Clinical outcome of high-grade non-muscle-invasive bladder cancer: a long-term single center experience.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; BCG Vaccine; Carcinoma, Transitional Cell; Cause of Death; Chemotherapy, Adjuvant; Cohort Studies; Combined Modality Therapy; Cystectomy; Epirubicin; Female; Follow-Up Studies; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Muscle, Smooth; Neoplasm Invasiveness; Neoplasm Staging; Probability; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2009 |
Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumours.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Cystectomy; Cystoscopy; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Follow-Up Studies; Humans; Iatrogenic Disease; Male; Minimally Invasive Surgical Procedures; Risk Assessment; Rupture; Treatment Outcome; Urethra; Urinary Bladder; Urinary Bladder Neoplasms; Urologic Surgical Procedures, Male; Wounds, Penetrating | 2009 |
The role of Id-1 in chemosensitivity and epirubicin-induced apoptosis in bladder cancer cells.
Topics: Antibiotics, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Epirubicin; Humans; Inhibitor of Differentiation Protein 1; Transfection; Urinary Bladder Neoplasms | 2009 |
Protodynamic therapy for bladder cancer: in vitro results of a novel treatment concept.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Epirubicin; Humans; Hydrogen-Ion Concentration; Paclitaxel; Photochemotherapy; Urinary Bladder Neoplasms; Urocanic Acid | 2009 |
Time-lapse live cell imaging and flow analysis of multidrug resistance reversal by verapamil in bladder cancer cell lines.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Nucleus; Cytoplasm; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Flow Cytometry; Humans; Microscopy, Confocal; Urinary Bladder Neoplasms; Verapamil | 2009 |
Drug eruption due to intravesical instillations of both epirubicin and mitomycin C.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Drug Eruptions; Epirubicin; Humans; Male; Middle Aged; Mitomycin; Urinary Bladder Neoplasms | 2009 |
Multidrug resistance in a urothelial cancer cell line after 1-hour mitomycin C exposure.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Epirubicin; Humans; Mitomycin; Time Factors; Urinary Bladder Neoplasms | 2009 |
What is the optimal treatment strategy for T1 bladder tumors?
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma; Cystectomy; Disease Progression; Disease-Free Survival; Epirubicin; Humans; Interferon alpha-2; Interferon-alpha; Neoplasm Recurrence, Local; Neoplasm Staging; Practice Guidelines as Topic; Recombinant Proteins; Reoperation; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Tumor Burden; Urinary Bladder Neoplasms | 2010 |
[Complete response to M-FAP chemotherapy for multiple lung metastases after segmental resection of urachal carcinoma : a case report].
Topics: Adenocarcinoma; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Fluorouracil; Humans; Lung Neoplasms; Male; Methotrexate; Urachus; Urinary Bladder Neoplasms | 2010 |
Re: Richard J. Sylvester, Maurizio A. Brausi, Wim J. Kirkels, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmett
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Drug Therapy, Combination; Epirubicin; Humans; Urinary Bladder Neoplasms | 2010 |
2-micrometer continuous wave laser treatment for multiple non-muscle-invasive bladder cancer with intravesical instillation of epirubicin.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Combined Modality Therapy; Epirubicin; Female; Humans; Laser Therapy; Male; Middle Aged; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2011 |
Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma; Combined Modality Therapy; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Risk Factors; Sex Factors; Smoking; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Surgical Procedures | 2011 |
Effect of maintenance chemotherapy with gemcitabine and paclitaxel on recurrent squamous cell carcinoma of the bladder: a case report.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cystectomy; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Japan; Male; Methotrexate; Middle Aged; Paclitaxel; Prognosis; Recurrence; Remission Induction; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2011 |
Expression of TRAIL, DR4, and DR5 in bladder cancer: correlation with response to adjuvant therapy and implications of prognosis.
Topics: Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Epirubicin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Prognosis; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Urinary Bladder Neoplasms | 2012 |
An epirubicin-conjugated nanocarrier with MRI function to overcome lethal multidrug-resistant bladder cancer.
Topics: Animals; Cell Death; Cell Line, Tumor; Cell Membrane; Cell Nucleus; Contrast Media; Cross-Linking Reagents; Drug Carriers; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Human Umbilical Vein Endothelial Cells; Humans; Magnetic Resonance Imaging; Magnetics; Mice; Nanostructures; Phantoms, Imaging; Tissue Distribution; Treatment Outcome; Urinary Bladder Neoplasms | 2012 |
Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Epirubicin; Female; Humans; Indoles; Mice; Neoplasm Metastasis; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2012 |
Impact of surgery and epirubicin intravesical chemotherapy on peripheral blood dendritic cell subsets in patients with superficial urothelial carcinoma of the bladder.
Topics: Adult; Aged; China; Dendritic Cells; Epirubicin; Female; Humans; Male; Middle Aged; Urinary Bladder Neoplasms | 2012 |
Lentivirus-mediated RNA interference of clusterin enhances the chemosensitivity of EJ bladder cancer cells to epirubicin in vitro.
Topics: Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Movement; Cell Survival; Clusterin; Drug Resistance, Neoplasm; Epirubicin; G1 Phase Cell Cycle Checkpoints; Genetic Vectors; Humans; Lentivirus; RNA Interference; RNA, Small Interfering; Urinary Bladder Neoplasms | 2012 |
Cigarette smoking status at diagnosis and recurrence in intermediate-risk non-muscle-invasive bladder carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma; Combined Modality Therapy; Cystectomy; Disease-Free Survival; Epirubicin; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Proportional Hazards Models; Risk Factors; Smoking; Time Factors; Urinary Bladder Neoplasms | 2013 |
Progesterone: a novel adjunct to intravesical chemotherapy.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Humans; Microscopy, Confocal; Progesterone; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Urothelium | 2002 |
Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Cystectomy; Doxorubicin; Epirubicin; Evidence-Based Medicine; Humans; Lymphatic Metastasis; Methotrexate; Neoplasm Invasiveness; Randomized Controlled Trials as Topic; Survival Analysis; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Intravesical pH: a potentially important variable affecting efficacy and the further development of anthracycline chemotherapy for superficial bladder cancer.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Epirubicin; Flow Cytometry; Humans; Hydrogen-Ion Concentration; Multidrug Resistance-Associated Proteins; Tumor Cells, Cultured; Urinary Bladder; Urinary Bladder Neoplasms; Verapamil | 2002 |
Epirubicin and meglumine gamma-linolenic acid: a logical choice of combination therapy for patients with superficial bladder carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cell Division; Drug Synergism; Epirubicin; Flow Cytometry; gamma-Linolenic Acid; Humans; Meglumine; Microscopy, Confocal; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2003 |
Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Division; Cell Line, Tumor; Clinical Trials as Topic; Comet Assay; Deoxycytidine; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Epirubicin; Flow Cytometry; Gemcitabine; Humans; Inhibitory Concentration 50; Mutation; Rhodamines; Time Factors; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms | 2004 |
Conservative management of mucosal prostatic urethral involvement in patients with superficial transitional cell carcinoma of the bladder.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Epirubicin; Follow-Up Studies; Humans; Male; Middle Aged; Mucous Membrane; Neoplasms, Multiple Primary; Prostatic Neoplasms; Urethral Neoplasms; Urinary Bladder Neoplasms | 2004 |
[Signet ring cell carcinoma of the urinary bladder: a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Epirubicin; Humans; Male; Methotrexate; Neoplasm Staging; Treatment Outcome; Ureterostomy; Urinary Bladder Neoplasms; Urinary Diversion; Vinblastine | 2004 |
15-year experience on intravesical therapy of T1G3 urinary bladder cancer: a conservative approach.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Disease Progression; Doxorubicin; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Survival Rate; Urinary Bladder Neoplasms | 2004 |
Effect of intravesical instillation on performance of uCYT+ test.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vaccine; Biopsy; Carcinoma, Transitional Cell; Epirubicin; Female; Humans; Male; Middle Aged; Sensitivity and Specificity; Urinary Bladder; Urinary Bladder Neoplasms; Urine | 2004 |
One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe?
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cystectomy; Cystoscopy; Epirubicin; Fatal Outcome; Humans; Male; Neoplasm Staging; Postoperative Period; Treatment Outcome; Urinary Bladder Neoplasms | 2004 |
Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coloring Agents; Combined Modality Therapy; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Hyperthermia, Induced; Indolequinones; Mitomycin; Tetrazolium Salts; Thiazoles; Urinary Bladder Neoplasms | 2005 |
The nuclear membrane in multidrug resistance: microinjection of epirubicin into bladder cancer cell lines.
Topics: Antibiotics, Antineoplastic; Cell Nucleus; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Humans; Microinjections; Microscopy, Confocal; Nuclear Envelope; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2005 |
The current status of perioperative chemotherapy for invasive bladder cancer: a multiinstitutional retrospective study in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cystectomy; Doxorubicin; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2005 |
Bladder cancer "adjuvant-lite": tastes great (works as well) and less filling (less toxic)?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dose-Response Relationship, Drug; Epirubicin; Humans; Methotrexate; Urinary Bladder Neoplasms; Vinblastine | 2005 |
Re: Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906).
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Clinical Trials, Phase III as Topic; Epirubicin; Humans; Mathematical Computing; Multicenter Studies as Topic; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Randomized Controlled Trials as Topic; Reproducibility of Results; Sample Size; Urinary Bladder Neoplasms | 2005 |
[Invasive bladder cancer recurrenced 5 years after complete response status by chemotherapy and radiotherapy: a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Cystectomy; Epirubicin; Humans; Neoplasm Recurrence, Local; Remission Induction; Time Factors; Urinary Bladder Neoplasms | 2005 |
Watchful waiting for low-grade Ta bladder tumours: the idea would have been unacceptable 30 years ago, but nowadays we are highly interested in the results of this study exploring it.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Papillary; Epirubicin; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Randomized Controlled Trials as Topic; Transurethral Resection of Prostate; Urinary Bladder Neoplasms; Urothelium | 2006 |
Conservative treatment of high grade superficial bladder tumours.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma, Transitional Cell; Epirubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Urinary Bladder Neoplasms | 2005 |
Furosemide reverses multidrug resistance status in bladder cancer cells in vitro.
Topics: Antibiotics, Antineoplastic; Cell Death; Cell Division; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Furosemide; Humans; Microscopy, Confocal; Sodium Potassium Chloride Symporter Inhibitors; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2006 |
Vitamin D receptor agonists, cancer and the immune system: an intricate relationship.
Topics: Calcitriol; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Doxorubicin; Drug Synergism; Epirubicin; Gemcitabine; Humans; Molecular Structure; Receptors, Calcitriol; Structure-Activity Relationship; Urinary Bladder Neoplasms | 2006 |
Meglumine Eicosapentaenoic acid (MeEPA) a new soluble omega-3 fatty acid formulation: in vitro bladder cancer cytotoxicity tests in combination with epirubicin and mitomycin.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Combinations; Drug Screening Assays, Antitumor; Drug Synergism; Eicosapentaenoic Acid; Epirubicin; Fatty Acids, Omega-3; Humans; Meglumine; Mitomycin; Urinary Bladder Neoplasms | 2006 |
[Superficial bladder carcinoma -- trend of less aggressive therapies].
Topics: Antibiotics, Antineoplastic; Carcinoma, Papillary; Carcinoma, Transitional Cell; Cystoscopy; Epirubicin; Follow-Up Studies; Humans; Neoplasm Recurrence, Local; Papilloma; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Urinary Bladder Neoplasms | 2006 |
[Adriamycin and mitomycin dose-dependently downregulate X-kinked inhibitor of apoptosis protein in human bladder cancer cells].
Topics: Antibiotics, Antineoplastic; Apoptosis; Cell Line, Tumor; Dose-Response Relationship, Drug; Epirubicin; Humans; Mitomycin; Urinary Bladder Neoplasms; X-Linked Inhibitor of Apoptosis Protein | 2006 |
A chemosensitivity test for superficial bladder cancer based on three-dimensional culture of tumour spheroids.
Topics: Antineoplastic Agents; Ciprofloxacin; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epirubicin; Humans; Mitomycin; Spheroids, Cellular; Thiotepa; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Verapamil | 2007 |
Reactivation of hepatitis in a bladder cancer patient receiving chemotherapy.
Topics: Antineoplastic Agents; Cisplatin; Epirubicin; Female; Hepatitis B; Humans; Methotrexate; Middle Aged; Recurrence; Urinary Bladder Neoplasms | 2007 |
Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Paclitaxel; Salvage Therapy; Urinary Bladder Neoplasms; Vinblastine | 2007 |
[New therapeutics in the suppression of superficial bladder carcinoma].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma, Papillary; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Mitomycin; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
[Clinical study of combination chemotherapy of methotrexate, epirubicin and nedaplatin (MEN) in patients with advanced urothelial carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Administration Schedule; Epirubicin; Female; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Methotrexate; Middle Aged; Organoplatinum Compounds; Quality of Life; Remission Induction; Survival Rate; Urinary Bladder Neoplasms | 2007 |
General clinical practice intraoperative intravesical epirubicin: implementing the process.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Epirubicin; Humans; Intraoperative Care; Medical Waste Disposal; New South Wales; Nurse's Role; Nursing Staff, Hospital; Operating Room Nursing; Protective Clothing; Urinary Bladder Neoplasms; Urinary Catheterization | 2007 |
Multidrug resistance in a urothelial cancer cell line after 3, 1-hour exposures to mitomycin C.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epirubicin; Follow-Up Studies; Humans; Intracellular Fluid; Mitomycin; Phenotype; Spheroids, Cellular; Time Factors; Urinary Bladder Neoplasms | 2007 |
Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Humans; Immunohistochemistry; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Proportional Hazards Models; Receptor, ErbB-2; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium; Vinblastine | 2007 |
Re: The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy.
Topics: Administration, Intravesical; Antineoplastic Agents; Combined Modality Therapy; Cystectomy; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2008 |
[Intravesical chemotherapy with 4'-Epi-Adriamycin in patients with superficial bladder tumors].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Doxorubicin; Epirubicin; Female; Humans; Male; Middle Aged; Urinary Bladder; Urinary Bladder Neoplasms | 1984 |
M-VEC (methotrexate, vinblastine, 4'-epirubicin and cisplatin) combined with glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the treatment of transitional cell carcinoma of urothelium: reduction in toxicity produced by r
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Epirubicin; Female; Glycosylation; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Male; Methotrexate; Middle Aged; Recombinant Proteins; Survival Analysis; Thrombocytopenia; Urinary Bladder Neoplasms; Vinblastine | 1994 |
Relative cytotoxicities of adriamycin and epirubicin in combination with lonidamine against human bladder cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Doxorubicin; Drug Resistance, Multiple; Epirubicin; Humans; Indazoles; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1995 |
[Complete response of lung metastasis from bladder cancer by combination chemotherapy with methotrexate, epirubicin and cisplatin: a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Epirubicin; Humans; Lung Neoplasms; Male; Methotrexate; Remission Induction; Urinary Bladder Neoplasms | 1995 |
Multimodal treatment of locally advanced transitional cell bladder carcinoma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Combined Modality Therapy; Epirubicin; Female; Fluorouracil; Humans; Male; Urinary Bladder Neoplasms | 1994 |
Trial with bacillus Calmette-Guérin and epirubicin combination in the prophylaxis of superficial bladder cancer.
Topics: Administration, Intravesical; Adult; Aged; BCG Vaccine; Carcinoma, Transitional Cell; Combined Modality Therapy; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 1994 |
[Adjuvant chemotherapy in infiltrating bladder carcinoma. Long-term results].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Epirubicin; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Survival Rate; Urinary Bladder Neoplasms; Vinblastine | 1993 |
Intra- and perivesical tumor growth in preoperative staging of bladder cancer: the role of transrectal ultrasonography and high resolution magnetic resonance imaging.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Epirubicin; Female; Humans; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Neoplasm Staging; Preoperative Care; Rectum; Sensitivity and Specificity; Ultrasonography; Urinary Bladder Neoplasms; Vinblastine | 1993 |
Non-P-glycoprotein-mediated atypical multidrug resistance in a human bladder cancer cell line.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Carcinoma, Transitional Cell; Cisplatin; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Fluorouracil; Humans; Mitomycin; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Selection, Genetic; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Verapamil; Vinca Alkaloids | 1995 |
The importance urinary glycosaminoglycan as a marker for superficial bladder tumors.
Topics: Adult; BCG Vaccine; Biomarkers, Tumor; Combined Modality Therapy; Creatinine; Epirubicin; Female; Follow-Up Studies; Glycosaminoglycans; Humans; Immunologic Factors; Interferon Type I; Male; Middle Aged; Predictive Value of Tests; Recombinant Proteins; Remission Induction; Sensitivity and Specificity; Treatment Outcome; Urinary Bladder Neoplasms | 1995 |
[Transitional carcinoma of the bladder at the T1G3 stage: personal experience].
Topics: Antibiotics, Antineoplastic; BCG Vaccine; Biopsy; Carcinoma, Transitional Cell; Combined Modality Therapy; Endoscopy; Epirubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms | 1996 |
[T1G3 bladder tumors: 5 years later].
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystectomy; Disease-Free Survival; Endoscopy; Epirubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms | 1996 |
Intra-arterial chemotherapy for muscle-invasive urinary bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Epirubicin; Female; Humans; Infusions, Intra-Arterial; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Tomography, Emission-Computed, Single-Photon; Urinary Bladder Neoplasms; Vinblastine | 1996 |
Determination and reversal of resistance to epirubicin intravesical chemotherapy. A flow cytometric model.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Fluorescence; Humans; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Verapamil | 1996 |
Determination and reversal of resistance to epirubicin intravesical chemotherapy. A confocal imaging study.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Fluorescence; Humans; Microscopy, Confocal; Sensitivity and Specificity; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Verapamil | 1996 |
Conservative management of stage T2 or T3a bladder cancer with deep transurethral resection followed by four cycles of chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Epirubicin; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 1996 |
Localization of anthracycline accumulation in sensitive and resistant urothelial tumor cell lines.
Topics: Antibiotics, Antineoplastic; Drug Resistance, Neoplasm; Epirubicin; Humans; Mitoxantrone; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1996 |
Intravesical instillation of epirubicin.
Topics: Administration, Intravesical; Epirubicin; Humans; Urinary Bladder Neoplasms | 1996 |
[The efficacy of ATP sensitivity assay on intravesical prophylactic instillation for superficial bladder cancer].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents; Doxorubicin; Drug Screening Assays, Antitumor; Epirubicin; Female; Humans; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 1996 |
Role of P-glycoprotein in chemoresistant superficial bladder tumours.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antibodies, Monoclonal; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Carcinoma, Transitional Cell; Drug Resistance, Neoplasm; Epirubicin; Female; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Urinary Bladder Neoplasms | 1997 |
[Neoadjuvant intra-arterial chemotherapy based on chemosensitivity tests for locally invasive bladder cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Drug Administration Schedule; Drug Screening Assays, Antitumor; Epirubicin; Etoposide; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Mitomycin; Peplomycin; Prognosis; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vinblastine | 1997 |
Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional cell bladder tumours.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Epirubicin; Extravasation of Diagnostic and Therapeutic Materials; Humans; Neoplasm Recurrence, Local; Urinary Bladder; Urinary Bladder Neoplasms | 1997 |
Bladder cancer recurrence by implantation of exfoliated cells: is gamma-linolenic acid an effective tumoricidal agent?
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Cell Adhesion; Drug Resistance, Neoplasm; Epirubicin; gamma-Linolenic Acid; Humans; Mitomycin; Neoplasm Recurrence, Local; Neoplasm Seeding; Serum Albumin; Tumor Cells, Cultured; Tumor Stem Cell Assay; Urinary Bladder Neoplasms; Water | 1998 |
[Intravesical instillation of epirubicin in the prophylactic treatment of recurrent superficial bladder cancer].
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cystectomy; Epirubicin; Humans; Neoplasm Recurrence, Local; Retrospective Studies; Urinary Bladder Neoplasms | 1998 |
Estramustine reversal of resistance to intravesical epirubicin chemotherapy.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Carcinoma, Transitional Cell; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Estramustine; Flow Cytometry; Fluorescence; Humans; Microscopy, Confocal; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 1999 |
Perivesical fat necrosis after adjuvant intravesical chemotherapy.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cystectomy; Epirubicin; Fat Necrosis; Female; Humans; Male; Middle Aged; Mitomycin; Urinary Bladder Neoplasms | 1999 |
Transmurally absorbed intravesical chemotherapy with dimethylsulfoxide in an animal model.
Topics: Administration, Intravesical; Animals; Antibiotics, Antineoplastic; Carcinogens; Dimethyl Sulfoxide; Disease Models, Animal; Epirubicin; Excipients; Hyperplasia; Male; Methylnitrosourea; Mucous Membrane; Rats; Rats, Wistar; Urinary Bladder; Urinary Bladder Neoplasms | 1999 |
Allergic contact dermatitis due to epirubicin.
Topics: Aged; Antibiotics, Antineoplastic; Dermatitis, Allergic Contact; Drug Eruptions; Epirubicin; Humans; Male; Patch Tests; Urinary Bladder Neoplasms | 1999 |
Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bisbenzimidazole; Down-Regulation; Doxorubicin; Drug Synergism; Epirubicin; Fluorescent Dyes; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Isoenzymes; Membrane Glycoproteins; Recombinant Proteins; RNA, Messenger; Staining and Labeling; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Urinary Bladder Neoplasms | 1999 |
The prognostic value of peripheral blood lymphocyte subsets in patients with bladder carcinoma treated using neoadjuvant M-VEC chemotherapy.
Topics: Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Epirubicin; Female; Humans; Leukocytes, Mononuclear; Lymphocyte Subsets; Male; Methotrexate; Middle Aged; Prognosis; Urinary Bladder Neoplasms; Vinblastine | 1999 |
TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Resistance, Multiple; Epirubicin; Female; Genes, p53; Humans; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Predictive Value of Tests; Prognosis; Retrospective Studies; Survival Rate; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms; Vinblastine | 1999 |
Small cell carcinoma of the bladder: long term outcome with integrated chemoradiation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Epirubicin; Female; Humans; Male; Middle Aged; Retrospective Studies; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 1999 |
Long term follow-up of combined radiochemotherapy for locally advanced bladder carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Epirubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Invasiveness; Patient Compliance; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2000 |
[Study of neoadjuvant chemotherapy for invasive bladder cancer with MEC (methotrexate, epirubicin, cisplatin) therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Drug Administration Schedule; Epirubicin; Humans; Leukopenia; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Prognosis; Survival Analysis; Thrombocytopenia; Urinary Bladder Neoplasms | 2001 |
Re: methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial.
Topics: Administration, Intravesical; Antineoplastic Agents; Black or African American; Carcinoma, Transitional Cell; Clinical Trials, Phase III as Topic; Drug Resistance; Epirubicin; Humans; Hydrogen-Ion Concentration; Mitomycin; Multicenter Studies as Topic; Osmolar Concentration; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms | 2001 |
Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin is not indicated for superficial bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Drug Therapy, Combination; Epirubicin; Female; Humans; Male; Middle Aged; Urinary Bladder Neoplasms | 2001 |
Frequency of positive biopsies after visual disappearance of superficial bladder cancer marker lesions.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; BCG Vaccine; Biopsy; Carcinoma, Transitional Cell; Clinical Protocols; Clinical Trials, Phase II as Topic; Cystoscopy; Epirubicin; Humans; Mitomycin; Neoplasm Recurrence, Local; Neoplasm, Residual; Urinary Bladder Neoplasms | 2001 |
Intravesical epirubicin treatment following TUR in superficial bladder tumours.
Topics: Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Postoperative Care; Urethra; Urinary Bladder Neoplasms; Urologic Surgical Procedures | 2001 |
[Evaluation of side effects after intrabladder instillations of preparations in patients with superficial bladder carcinoma].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BCG Vaccine; Doxorubicin; Epirubicin; Female; Humans; Male; Middle Aged; Poland; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2002 |
DNA ploidy and S-phase fraction as predictive factors of response and outcome following neoadjuvant methotrexate, vinblastine, epirubicin and cisplatin (M-VEC) chemotherapy for invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Disease-Free Survival; DNA, Neoplasm; Epirubicin; Female; Flow Cytometry; Humans; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Ploidies; S Phase; Survival Rate; Urinary Bladder Neoplasms; Vinblastine | 2002 |
[Retrospective survey of pharmacologic tolerance in the prevention of neoplastic recurrence of superficial urothelioma].
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Humans; Interferons; Mitomycin; Neoplasm Recurrence, Local; Retrospective Studies; Urinary Bladder Neoplasms | 1992 |
[A effective combination preoperative intraarterial infusion chemotherapy and irradiation for advanced sigmoid colon cancer with bladder invasion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Epirubicin; Humans; Infusions, Intra-Arterial; Iodized Oil; Male; Middle Aged; Neoplasm Invasiveness; Preoperative Care; Sigmoid Neoplasms; Tegafur; Uracil; Urinary Bladder Neoplasms | 1992 |
Tissue polypeptide antigen for monitoring of advanced bladder cancer after MVEC chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Peptides; Sensitivity and Specificity; Tissue Polypeptide Antigen; Urinary Bladder Neoplasms; Vinblastine | 1992 |
[Is down-staging of advanced bladder cancer by neoadjuvant chemotherapy possible?--MVEC protocol].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cystectomy; Epirubicin; Female; Follow-Up Studies; Humans; Male; Methotrexate; Middle Aged; Neoplasm Staging; Survival Rate; Urinary Bladder Neoplasms; Vinblastine | 1992 |
[Intra-arterial infusion chemotherapy of advanced bladder cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cisplatin; Drug Administration Schedule; Epirubicin; Etoposide; Female; Humans; Infusions, Intra-Arterial; Male; Prognosis; Urinary Bladder Neoplasms | 1992 |
[Plasma concentration of 4'-epi-adriamycin in hemodialysis patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Humans; Kidney Failure, Chronic; Methotrexate; Middle Aged; Renal Dialysis; Urinary Bladder Neoplasms; Vinblastine | 1992 |
A pilot study comparing different dose levels and administration schedules of interferon-alpha 2b combined with epirubicin for prevention of recurrence in bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Humans; Interferon alpha-2; Interferon-alpha; Pilot Projects; Recombinant Proteins; Recurrence; Urinary Bladder Neoplasms | 1992 |
Methotrexate, vinblastine, epidoxorubicin and cisplatin (M-VEC) in patients with locally advanced transitional bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Urinary Bladder Neoplasms; Vinblastine | 1991 |
[Intra-arterial infusion chemotherapy for advanced bladder cancer and prostate cancer using reservoir system].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Epirubicin; Etoposide; Female; Humans; Infusion Pumps; Infusions, Intra-Arterial; Male; Middle Aged; Prognosis; Prostatic Neoplasms; Urinary Bladder Neoplasms | 1991 |
Organ conservation in bladder cancer.
Topics: Administration, Intravesical; Combined Modality Therapy; Drug Administration Schedule; Epirubicin; Humans; Mitomycin; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 1991 |
Intravesical sequential combination of epirubicin and interferon alpha-2b in patients affected by superficial transitional cell carcinoma of the bladder. Results of a pilot study at Palermo University and proposal of a basic research.
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Administration Schedule; Epirubicin; Follow-Up Studies; Humans; Interferon alpha-2; Interferon-alpha; Neoplasm Recurrence, Local; Pilot Projects; Recombinant Proteins; Urinary Bladder Neoplasms | 1991 |
Phase 1/2 study of intravesical epirubicin in patients with carcinoma in situ of the bladder.
Topics: Administration, Intravesical; Carcinoma in Situ; Drug Evaluation; Epirubicin; Humans; Neoplasm Recurrence, Local; Survival Rate; Urinary Bladder Neoplasms | 1991 |
Systemic chemotherapy for urothelial cancer in patients with ureteric obstruction.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Creatinine; Doxorubicin; Epirubicin; Humans; Leukopenia; Methotrexate; Middle Aged; Neoplasm Staging; Ureteral Obstruction; Urinary Bladder Neoplasms; Vinblastine | 1991 |
Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Epirubicin; Humans; Interferon-gamma; Mitomycin; Mitomycins; Radioimmunoassay; Urinary Bladder Neoplasms | 1990 |
Phase I/II study of intravesical epirubicin in patients with carcinoma in situ of the bladder.
Topics: Administration, Intravesical; Biopsy; Carcinoma in Situ; Combined Modality Therapy; Drug Evaluation; Epirubicin; Humans; Urinary Bladder Neoplasms | 1990 |
[Nonspecific immunotherapy with BCG vaccine in bladder tumors].
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Drug Evaluation; Epirubicin; Humans; Immunotherapy; Injections, Intradermal; Neoplasm Recurrence, Local; Postoperative Care; Urinary Bladder Neoplasms | 1990 |
[Possibilities and limits of chemotherapy in multi-modality treatment of urinary bladder cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Doxorubicin; Epirubicin; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Urinary Bladder Neoplasms; Vinblastine | 1989 |
[The M-VEC chemotherapy of advanced bladder tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Drug Evaluation; Epirubicin; Female; Humans; Male; Methotrexate; Middle Aged; Neoplasm Staging; Postoperative Care; Preoperative Care; Urinary Bladder Neoplasms; Vinblastine | 1989 |
[Adjuvant chemotherapy with biocisplatin, methotrexate and biocarbazine in advanced bladder tumors].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Dacarbazine; Drug Evaluation; Epirubicin; Follow-Up Studies; Humans; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Postoperative Care; Urinary Bladder Neoplasms; Vinblastine | 1989 |
A phase II study of 4-epi-adriamycin in advanced urothelial transitional cell cancer. EORTC-GU Group protocol 30867.
Topics: Adult; Aged; Carcinoma, Transitional Cell; Drug Evaluation; Epirubicin; Female; Humans; Leukopenia; Male; Middle Aged; Nausea; Thrombocytopenia; Urinary Bladder Neoplasms | 1989 |
Cardiac morphologic and functional changes induced by epirubicin chemotherapy.
Topics: Adult; Breast Neoplasms; Epirubicin; Female; Heart Diseases; Humans; Male; Middle Aged; Urinary Bladder Neoplasms | 1989 |
Epirubicin in treatment and recurrence prophylaxis of patients with superficial bladder cancer.
Topics: Administration, Intravesical; Carcinoma in Situ; Carcinoma, Papillary; Combined Modality Therapy; Epirubicin; Humans; Instillation, Drug; Neoplasm Recurrence, Local; Prognosis; Urinary Bladder; Urinary Bladder Neoplasms | 1989 |
Low dose intermittent 5-fluorouracil, epirubicin and cyclophosphamide (FEC) in poor risk patients with advanced transitional cell bladder cancer: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Male; Middle Aged; Pilot Projects; Risk Factors; Urinary Bladder Neoplasms | 1989 |
[Polychemotherapy using the M-VEC protocol (methotrexate, vinblastine, epirubicin, cisplatin) in advanced urinary bladder cancer--effectiveness and toxicity].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Epirubicin; Female; Humans; Male; Methotrexate; Neoplasm Metastasis; Neoplasm Staging; Urinary Bladder; Urinary Bladder Neoplasms; Vinblastine | 1989 |
Intravesical chemotherapy: studies on the relationship between osmolality and cytotoxicity.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Line; Cisplatin; Colony-Forming Units Assay; Doxorubicin; Epirubicin; Ethoglucid; Humans; In Vitro Techniques; Mitomycin; Mitomycins; Osmolar Concentration; Stereoisomerism; Thiotepa; Tumor Stem Cell Assay; Urinary Bladder Neoplasms | 1986 |
Intravesical chemotherapy. Studies on the relationship between pH and cytotoxicity.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Line; Cisplatin; Doxorubicin; Epirubicin; Ethoglucid; Humans; Hydrogen-Ion Concentration; Mitomycin; Mitomycins; Thiotepa; Tumor Stem Cell Assay; Urinary Bladder Neoplasms | 1986 |
Intravesical chemotherapy with 4'-epi-Adriamycin in patients with superficial bladder tumors.
Topics: Adult; Aged; Doxorubicin; Drug Evaluation; Epirubicin; Female; Humans; Male; Middle Aged; Prognosis; Urinary Bladder Neoplasms | 1986 |
[Cooperative phase II study of epirubicin (EPI) in bladder cancer, renal pelvic and ureteral tumors--Urological Cooperative Study Group of EPI].
Topics: Aged; Anorexia; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Epirubicin; Hemoglobins; Humans; Infant; Infusions, Intravenous; Kidney Neoplasms; Kidney Pelvis; Leukopenia; Male; Middle Aged; Ureteral Neoplasms; Urinary Bladder Neoplasms | 1986 |
Absorption of epi-doxorubicin after intravesical administration in patients with in situ transitional cell carcinoma of the bladder.
Topics: Absorption; Administration, Intravesical; Carcinoma, Transitional Cell; Doxorubicin; Epirubicin; Humans; Urinary Bladder Neoplasms | 1987 |
[Fundamental studies on intravesical instillation of 4'-epi-adriamycin for the treatment of bladder cancer].
Topics: Administration, Topical; Animals; Antibiotics, Antineoplastic; Dogs; Doxorubicin; Epirubicin; Humans; Mucous Membrane; Tissue Distribution; Tumor Stem Cell Assay; Urinary Bladder; Urinary Bladder Neoplasms | 1985 |